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ABSTRACT 
 
 Plasmodium falciparum is a human intracellular parasite that is the causative 
agent of a deadly form of malaria.  This species alone is responsible for 200 million 
cases of malaria annually resulting in over 1 million deaths worldwide.  The excessive 
mortality due to P. falciparum infection is due to its ability to cause severe pathogenesis 
through hyperparasitemia and cytoadherence defined as the ability of infected red blood 
cells to adhere to host vasculature.  Cytoadherence is mediated through the export of 
parasite proteins to the surface of the infected red blood cell (RBC).  Exported proteins 
have been identified but the pathway for protein export is still being elucidated.   
 Many protein coding genes in the P. falciparum genome are hypothetical and 
therefore still need to be studied.  Random transposon mutagenesis using the piggyBac 
transposable element in P. falciparum has given us a library of mutants to use for 
forward genetic studies.  In this work, we describe a novel approach for screening P. 
falciparum piggyBac mutants to look for differences in cytoadherence.  We utilized an 
image-based approach in order to quantify cytoadherence in P. falciparum NF54 wild-
type and thirty-four piggyBac mutants.  We found cytoadherence to be affected by the 
expression of genes with specific gene ontologies including nucleic acid metabolism 
and post-translational modification.  Many of these genes are annotated as hypothetical 
viii 
 
or putative and this work may result in further revelations of a role for these genes in 
parasite pathogenesis.   
 We further characterized a piggyBac mutant that was increased in cytoadherent 
abilities as an atypical mitogen-activated protein kinase phosphatase (MKP) named 
PfMKP1. We were able to demonstrate phosphatase activity in a generic substrate-
based assay and identify a putative substrate as mitogen-activated protein kinase 1 
(Pfmap1).  Furthermore, we found Pfmap1 to be differentially phosphorylated and a 
difference in localization (through immunofluorescence assay) in the PfMKP1 mutant 
line compared to the wild-type and complemented mutant.  This adds to the recent work 
characterizing this gene as important in cell cycle progression within the erythrocytic 
cycle and lends to the hypothesis of a functioning mitogen-activated protein kinase 
(MAPK) pathway in P. falciparum for which it is currently unknown.   
 Supplementary work focused on the development of tools to further investigate 
the MAPK pathway and the role for PfMKP1 as an atypical MKP of Pfmap1 in this 
pathway.  A mass spectrometry-based technique was developed to look at Pfmap1 and 
its potential active state based on its phosphorylation status.  This approach needs 
further development but the methods are described here within.  In addition, the tools 
needed to further characterize the binding interaction between PfMKP1 and Pfmap1 
were established.  The mass spectrometry screen and immunofluorescence screening 
of Pfmap1 can further our knowledge of the MAPK pathway in P. falciparum and lead to 
the identification of external stimuli that can induce growth or stress response in the 
parasite.  Taken together, the elucidation of mechanisms for cytoadherence and signal 
transduction pathways in the parasite can lead to new drug target identification.   
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CHAPTER ONE: 
INTRODUCTION 
 
Background 
 Malaria is one of the oldest diseases known to man, and yet it still causes more 
than  200 million cases annually resulting in over 1 million deaths worldwide (51).  The 
causative agent of malaria is a group of apicomplexan parasites in the genus 
Plasmodium.  Plasmodium contains many species that cause disease in a range of 
animals from reptiles, to birds, to mammals including rodents, non-human primates, and 
humans.  Five species are known to cause human malaria including P. falciparum, P. 
vivax, P. ovale, P. malariae, and P. knowlesi which is a zoonotic infection (51).  Of these 
five species, P. falciparum and P. vivax cause the highest morbidity worldwide while P. 
falciparum is responsible for the highest amount of mortality (2, 51, 89).  P. falciparum is 
mostly found in sub-Saharan Africa where children under the age of five and pregnant 
women are most likely to succumb to the disease (51).  Malaria is both preventable and 
curable but further research into the biology of the parasite is paramount for the 
development of new drug treatments and vaccine development.   
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 Parasite Life Cycle 
 The life cycle of the Plasmodium parasite is complex and involves both an 
arthropod definitive host and a human intermediate host (Fig. 1.1) (1).  Malaria infection 
is initiated by the bite of an infected female Anopheles mosquito which injects 
sporozoites into the bloodstream during a blood meal.  The sporozoites find their way to 
the host’s liver where they invade the sinusoidal layer and eventually a hepatocyte to 
complete the exo-erythrocytic cycle.  Once in the hepatocyte, the sporozoite matures 
into a very large form called a liver schizont.  The schizont bursts and releases 
thousands of merozoites into the bloodstream.   The merozoites go on to invade 
erythrocytes where they begin rapid asexual reproduction in the erythrocytic cycle.  
Within the erythrocyte, the merozoite undergoes a period of growth before DNA 
replication and schizogony occurs.  During schizogony, a schizont segments into a large 
number of merozoites which eventually burst the cell and are released into the 
bloodstream.  After reinvasion into an erythrocyte, the individual parasites choose to 
either undergo another round of asexual reproduction or to differentiate into a pre-
sexual form called the gametocyte.  The default pathway is to continue the erythrocytic 
cycle building up increased parasitemia in the host.  For P. falciparum, the life cycle in 
the erythrocyte is approximately 48 hours.  The asexual reproduction within erythrocytes 
is the pathogenic stage in the human host and will be the focus of this work. 
 If the sexual pathway is turned on, a gametocyte is formed which undergoes 
stages of maturity within the human host.  During these stages, gametocytes have been 
found to sequester in bone marrow (10) however, by the time they reach full maturity, 
gametocytes can be found in peripheral blood smears indicating that they can be 
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ingested by another Anopheles mosquito taking a blood meal.  Once in the mosquito 
the gametocyte undergoes further maturation into a micro- or a macrogamete.  The 
microgamete exflagellates within the midgut of the mosquito and enters the 
macrogamete forming a zygote.  The zygote further differentiates into an ookinete and 
enters the midgut of the mosquito where it develops into an oocyst.  The oocyst 
ruptures to release sporozoites which travel to the salivary gland of the mosquito where 
they are available to infect another human host when the mosquito takes another blood 
meal.  The sexual reproductive pathway is important in transmission of malaria.        
  
 Uncomplicated Malaria 
 Most patients infected with the malaria parasites will not show any visible signs 
or symptoms.  The disease state of malaria is caused by asexual reproduction of the 
parasite in the erythrocytes of the host.  There the parasites undergo the erythrocytic 
cycle during which they degrade and burst red blood cells (RBCs).  A characteristic 
relapsing fever or paroxysm is apparent in the host as the immune system mounts a 
response when schizonts burst RBCs to release the newly formed merozoites (74).  The 
loss of RBCs due to the parasitism of the host cell causes general malaise and can lead 
to anemia (3, 57).  In addition, the high turnover rate of the RBCs within the body leads 
to liver and spleen enlargement (129).  Once the parasites are cleared from the 
bloodstream by either drug treatment or the immune system, the host can fully 
convalesce with the exception of P. vivax and P. ovale which can cause a relapse in 
disease years after the initial infection.   
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 Severe Malaria  
 Plasmodium falciparum continues to cause significant mortality in developing 
countries (51).  It causes the most deaths of the five Plasmodium sp. due to its ability to 
cause a severe form of malaria. The severity is due to its rapid growth cycle and ability 
to cytoadhere.  P. falciparum cases have the highest average parasitemia rate in the 
blood (10-100x that of the other species).  This high parasitemia contributes to severe 
fever paroxysms and anemia both of which can cause death (110).  In addition, the 
ability of the parasite to adhere to host vasculature in either the brain or in the placenta 
during pregnancy can cause cerebral or placental malaria.  Placental malaria can cause 
significant mortality to the mother and unborn child (110). Cerebral malaria develops 
quickly and can cause death rapidly if untreated (62). Cerebral malaria leads to 
seizures, coma and death in 30% of cases (110).  In children, a diagnosis of cerebral 
malaria indicates a poor prognosis indicating death or life-long sequela (110).     
  
 Diagnosis, Treatment, and Prevention 
 The gold standard for diagnosis of malaria remains to be microscopic evaluation 
of a blood smear and visual identification of the species of parasite (1).  Other 
diagnostics have come into use such as a molecular diagnosis using nested-PCR to 
determine the specific species of infection (109) or immunofluorescence assay in blood 
donations (115).  However, in rural clinics in resource poor countries; these methods 
are not viable options and diagnosis is made by symptoms alone during clinical 
observation of the patient (27).  This leads to misdiagnosis and incorrect distribution of 
anti-malarial drugs.   
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 Anti-malarial drugs are recommended for the treatment of malaria.  Anti-malarials 
that were once commonly used to treat malaria are now ineffective due to drug 
resistance in parasites (27).  Currently, artemisinin combination therapy (ACT) is 
recommended by the World Health Organization for the treatment of malaria.  To date, 
only one radical cure is currently being utilized in the clinical setting, the 8-
aminoquinolone primaquine but this compound exhibits high toxicity in persons with 
G6PD deficiency and is therefore not used for causal prophylaxis in P. falciparum 
infections.  In cases of severe malaria, oral drugs are not fast-acting enough and drugs 
must be given intravenously.  Current treatment of severe malaria is the intravenous 
application of artesunate (1).   
 Malaria is a mostly preventable infectious disease.  Prevention for non-immune 
travelers visiting endemic areas is typically a course of anti-malarials such as malarone, 
mefloquine, or chloroquine as well as the antibiotic doxycycline which is commonly used 
(1).  However, the majority of anti-malarial prophylactics are contraindicated for 
pregnant women and children.  In addition, prophylactics are not a viable option for 
those living in malaria endemic regions.  Currently, there is no vaccine approved for the 
prevention of malaria and those living in endemic countries can only utilize vector 
control methods, such as the widespread use of bed nets and insecticides.  
  
 Vaccine Development 
 A vaccine for the prevention of malaria is currently the holy grail of malaria 
eradication.  Recently, one vaccine candidate has undergone phase III clinical trials, the 
RTS,S subunit vaccine.  This vaccine utilizes a parasite antigen, the circumsporozoite 
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protein (CSP) Repeat region and T-cell epitope fused to the hepatitis B Surface antigen 
and mixed with free hepatitis B Surface antigen hence the name RTS,S.  The hepatitis 
B portion is dual in purpose in that it acts as a stimulant to the immune system for the 
malaria protein and also immunizes against hepatitis B.  In phase III trials, African 
infants and children were administered the vaccine and followed for a period of time.  
The children who received the vaccine were less likely to contract clinical and severe 
malaria however the efficacy of the vaccine was low, 50% for clinical malaria and less 
than 50% for severe malaria (9). The vaccine had less efficacy in trials of infants with a 
30% protective level for clinical malaria and less than 30% for severe malaria (8).   
  Additional vaccine candidates are actively being pursued in pre-clinical and 
phase I clinical studies (112).  Both subunit and whole organism antigens are being 
investigated including a duffy-binding protein (DBP) for P. vivax and an inactivated 
sporozoite vaccine for P. falciparum [8].  These vaccines mostly target sporozoite 
surface antigens aimed at reducing infection before the sporozoite can invade the host’s 
liver (112).  However, blood stage antigens and gametocyte antigens are also being 
targeted to prevent disease and transmission, respectively.   
  
 Drug Resistance and Discovery 
 Malaria drug resistance is best described for P. falciparum as it is the most 
deadly infection and treatment is imperative for survival.  Chloroquine-resistant P. 
falciparum is the most widespread form but combination antifolate, mefloquine, and 
atovoquone resistance have also emerged (27). The molecular basis for chloroquine, 
antifolate combination drugs, and atovaquone resistance has been well established.  
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Mutations in the target enzymes of these drugs allow for the parasite to become 
resistant by a number of mechanisms including increased efflux ability or inability to 
inhibit enzyme.   
 Because of drug resistance, the need for new drug development is high.  Many 
pathways have been targeted due to their uniqueness in the parasite including 
hemoglobin digestion and the folate pathway.  Mitochondrial function and respiration are 
also high value targets since the electron transport chain in Apicomplexa species differs 
from that of the mammalian host mitochondria.  However, there are other parasite 
pathways that have yet to be explored for drug discovery.   
 Currently, an area of focus for P. falciparum drug development is kinase 
inhibitors (30, 131).  With the success of kinase inhibitors as treatment for other disease 
models, much research is now being conducted to develop kinase inhibitors specifically 
targeting P. falciparum kinase activity.  Putative kinases and signaling pathways in P. 
falciparum have been identified through bioinformatic analysis (14, 127).  Many kinases 
have been found to be divergent from mammalian kinases which may indicate their 
usefulness as a drug target, including kinases that directly affect P. falciparum growth 
and reproduction within the host (33, 43, 58).  Recent advances in malaria research in 
fields such forward genetics and structure activity relationship chemistry allow for 
designer drugs which can target specific enzymes unique to P. falciparum.   
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Plasmodium falciparum Biology and Pathogenesis 
  
 Cytoadherence 
 P. falciparum is the only human malaria species known to cause severe disease 
in the form of cerebral malaria.  There are two non-exclusive hypotheses for the cause 
of cerebral malaria: 1) the P. falciparum-infected red blood cells (iRBCs) bind to host 
endothelial cells and other RBCs which physically block the blood vessels leading to 
vascular occlusion (12, 88); and 2) the iRBCs interact with host cells (endothelial or 
platelet) causing activation of the endothelial cells and engagement of the immune 
response that includes inflammation of the endothelial leading to blockage of the vessel 
(49).   The mechanism for both hypotheses involves the iRBC receptor-mediated 
attachment to host cells known as cytoadherence (120).   
 Cytoadherence of the host endothelial cells involves host cell receptors that allow 
for P. falciparum derived proteins on the surface of the iRBC to bind.  The endothelial 
receptors indicated in cerebral malaria are most notably CD36 and ICAM-1 (21, 52, 92, 
94).  However, the ability of the iRBC to bind to these receptors alone is not sufficient 
for cerebral malaria to occur.  Recently, a study linked CD36 adhesion of iRBCs to 
recruitment of integrin which further strengthened the cytoadhesion demonstrating how 
the first step in cerebral malaria may be cytoadhesion of iRBCs but a more complex 
system is necessary for disease (37).  
 On a molecular level, cytoadherence is caused by the export of parasite proteins 
to the RBC surface which then interact with receptors on the surface of host cells such 
as CD36, ICAM-1, VCAM, CSA and others.  P. falciparum makes and exports proteins 
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to the surface of the iRBC that are responsible for this interaction, most notably 
erythrocyte membrane protein 1 (PfEMP1).  It is clear that PfEMP1 is surface expressed 
and critical for binding to host cell receptors (26, 77, 82).  Other proteins directly 
involved in the surface exposure of PfEMP1 such as PfEMP3 and KAHRP are also 
known to affect cytoadherence (103, 125).  Many other proteins and organelle 
structures such as Maurer’s clefts that are vital to the expression and localization of 
these proteins are expressed and exported to the RBC cytoplasm by P. falciparum.  
Reports have been able to highlight the effects of some proteins but a clear picture of all 
the proteins involved in protein exportation to the RBC is still widely unknown due to the 
complexity of the system.  
 Knob structures.  Knob structures are electron-dense protrusions on the 
surface of the iRBC that contain proteins of parasite origin (11).  Knobs form as the 
parasite matures in the RBC (75).  Within the knobs, knob-associated histidine-rich 
protein (KAHRP), PfEMP1, and PfEMP3 interact and allow for the display of the variant 
PfEMP1 molecules on the surface of the RBC membrane.  Studies suggest that these 
structures play a role in increasing rigidity of the RBC due to their interaction with actin 
and spectrin in the RBC cytoskeleton (83).   Knob structures are directly implicated in 
the ability of the parasite to cytoadhere and the type of PfEMP1 that is expressed on the 
surface is responsible for the specificity of the adherence to host cell receptors such as 
CD36 (36).   
 Exported proteins.  P. falciparum exports a large repertoire of proteins during its 
development within the RBC including those in the knob structures.  There are 2 
mechanisms for protein export, Plasmodium export element (PEXEL)-dependent and 
10 
 
PEXEL-independent.  The parasite export pathway is complex, utilizing parasite-derived 
organelles in the RBC cytosol (Maurer’s clefts) and multiple export pathways (e.g. 
PEXEL motifs and classical vesicle exportation) that extend beyond the confines of the 
parasitophorous vacuole membrane (PVM) (28, 48).  Exported proteins are thought to 
follow the same initial path as found in other eukaryotic cells where the signal peptide is 
targeted to the endoplasmic reticulum which utilizes a vesicle budding system to 
translocate proteins across the cell membrane.  Enzymes like phosphatidylinositol 3-
phosphate found in the endoplasmic reticulum, aspartic proteases, and plasmepsin V 
play a role in the processing of PEXEL-motif proteins; however, these enzymes are not 
solely responsible for the export of parasite proteins (25, 29, 104).  
 Once proteins are packaged for export, they must be translocated across the 
plasma membrane (PM) and PVM into the RBC cytosol and beyond.  Proteins with a 
hydrophobic signal sequence followed by a PEXEL/HT motif, including KAHRP and 
PfEMP3, are exported to the RBC cytosol via a PTEX translocon in the PVM (38).    
Although PfEMP1 has a PEXEL motif, it lacks the hydrophobic sequence and there is 
no cleavage of the PEXEL motif to the mature N-terminus sequence which allows for 
exportation of PEXEL proteins (108).  Therefore, PfEMP1 is thought to represent a non-
PEXEL protein in its path of exportation (86).   Non-PEXEL exported proteins that 
contain a transmembrane domain are exported to the Maurer’s clefts in the RBC cytosol 
(13, 106) after passage through the parasite membrane and PVM as an unfolded 
protein (59).  Other proteins involved in this exportation pathway are still being 
determined, including the translocons responsible for non-PEXEL export out of the PV. 
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 Changes to the rigidity and deformability of the RBC occur when the parasite 
develops within the RBC, which in turn affects cytoadhesion of the iRBC and iRBC 
sequestration (117). Some exported parasite proteins affect cytoadherence by changing 
the RBC cytoskeleton (84).  PHIST proteins are a group of exported proteins within the 
Plasmodium helical interspersed subtelomeric family that are expanded to 72 paralogs 
in P. falciparum (105).  PHIST proteins stabilize proteins present in the electron-dense 
knobs of mature-parasite iRBCs responsible for cytoadherence as well as interact with 
RBC cytoskeleton to affect rigidity (85, 95).   
 P. falciparum erythrocyte membrane protein 1 (PfEMP1).  PfEMP1 is an 
exported parasite protein found on the surface of infected RBCs.  PfEMP1 is made early 
on in the parasite life cycle and is exported as the parasite matures.  There are 60 var 
genes that code for 60 different PfEMP1 molecules in P. falciparum.  These genes are 
monoallelic in expression meaning only one type of PfEMP1 molecule is found on the 
surface of an infected RBC (107).  Their expression is under tight control where 59 of 
the 60 genes are being actively repressed and only one gene is being actively 
transcribed (64). The expressed PfEMP1 molecule that is composed of several 
domains: the acid-terminal sequence (ATS) which is known to interact with KAHRP 
within the RBC, and the variable domains such as the cysteine-rich interdomain region 
(CIDR) and the duffy-binding like (DBL) domain which are responsible for the specificity 
of PfEMP1 binding to host cell receptors (76, 85, 122).  Although only one PfEMP1 
molecule is expressed at a given time, antigenic switching can occur where the parasite 
within the human host or within culture can switch the PfEMP1 being expressed which 
can change cytoadherent properties of the cell. 
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 PfEMP1 is exported into the RBC cytosol during infection.  It contains a PEXEL 
motif however it lacks the hydrophobic sequence that is necessary for PEXEL protein 
trafficking to the RBC cytosol and is therefore thought to be transported to the RBC 
through a different mechanism than PEXEL proteins such as KAHRP (69, 87, 111).  As 
of yet, the translocon that transports PfEMP1 across the PVM is not known.  However, it 
is known that PfEMP1 interacts with Maurer’s clefts where it assembles with the other 
knob associated proteins before it reaches its final destination at the surface of the RBC 
within the knob structures (93).    
 
 Signaling Pathways in Plasmodium falciparum 
 Signaling pathways allow cells to respond to external stimuli by regulating cellular 
processes (23).  In P. falciparum, signaling pathways are involved in cell cycle control, 
sexual differentiation, and pathogenic mechanisms such as host cell invasion and 
cytoadherence.  Specifically, calcium-dependent mechanisms for signaling have been 
implicated in invasion (67, 119) and phosphatidylinositol-dependent signaling has been 
found to be involved in hemoglobin digestion within the parasite (118).  Other signaling 
pathways based on phosphorylation cascades are currently being studied and are found 
to have significant cellular affects even though the mechanisms and entire pathways 
remain unclear.   
 Since the late 1970s, researchers have been investigating global phosphorylation 
dynamics of erythrocytes infected with Plasmodium sp. (34, 66, 90, 114, 128).  These 
first studies demonstrated the importance of phosphorylation pathways in Plasmodium 
infections and laid the ground work for future global phosphorylation studies.  Based on 
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these pre-mass spectrometry era proteomic studies, three major insights into 
phosphorylation patterns in Plasmodium species during the erythrocytic life cycle were 
discovered.  One, the state of phosphorylation is dependent on the stage of 
Plasmodium and changes over the course of the 48 hour life cycle (114, 128). Two, the 
parasite causes reversible changes in the phosphorylation of the RBC proteins during 
invasion and infection (90).  Three, phosphoproteins are species dependent (128).   
  
 P. falciparum kinome and phosphatome.  Bioinformatic analyses of the P. 
falciparum genome identified kinases belonging to all major eukaryotic kinase families, 
with the exception of tyrosine kinases and STE (STErile yeast) kinases (14, 124).  In 
these studies, 65 typical eukaryotic protein kinases (ePKs) and 99 protein kinase-like 
sequences were identified.  The atypical ePKs that were found are thought to be a 
previously unknown group of kinases that may be unique to Apicomplexan.  Because of 
their unknown function, these kinases are deemed “orphan” kinases (41).  Even kinases 
that have shown significant homology to other ePKs are divergent to the point where the 
substrate and function in P. falciparum is still unknown.   
 Phosphatases have also been elucidated through bioinformatic analysis of the P. 
falciparum genome.  Wilkes and Doerig identified 34 putative phosphatase sequences 
in P. falciparum which encode for phosphatases in all known groups of eukaryotic 
protein phosphatases and additional non-protein phosphatase groups (127).   However, 
certain protein sequences containing phosphatase domains were not identified in this 
study and therefore this study may reflect only a partial true Plasmodium phosphatome.  
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 Signaling pathways and cell cycle control.  It is controversial whether the 
Plasmodium erythrocytic cell cycle follows that of a typical eukaryote, i.e. distinct G1, S, 
G2, M phases (14, 16, 40).  However, the P. falciparum cell cycle is thought to be 
regulated by cyclin-dependent kinases (CDKs) in a similar manner to other eukaryotes. 
Evidence for this includes the fact that phosphorylation of proteins changes as the cell 
cycle progresses and specifically tyrosine phosphorylation which may play a major role 
in cell cycle development (96).  There are six CDK-related kinases identified in P. 
falciparum and 45 putative phosphoproteins substrates for the CDKs (96).  Two CDKs 
have been identified as localized in the nucleus where they can affect transcription and 
are critical in the asexual life cycle (7).  The P. falciparum CDK Pfmrk has greatest 
homology to human CDK7 and has been shown to form a complex with effector 
molecules (Pfcyc-1 and PfMAT-1) in the same way that CDK7 does in its active state 
(65).  Pfmrk is of current investigation as a novel drug target (24, 54, 97). 
 Other enzymes have been implicated in cell cycle control through genetic 
manipulation.   Attempts to knock out function of certain kinases within erythrocytic 
culture have failed.  For example, the inability to inactivate both Pfmap-2 and Pfcrk1 
suggests their essentiality in erythrocytic schizogony (43, 68, 99) although their direct 
target and pathway is still unknown.  Recently, phosphatases have also demonstrated 
importance in cell cycle control.  A putative mitogen-activated protein kinase 
phosphatase PfMKP1 was found to be involved in cell cycle control where the loss of 
expression of this phosphatase led to the delay of entry into the DNA synthesis phase 
(18) demonstrating a critical role for progression in the cell cycle. Another phosphatase 
was identified as causing a block in the G2/M phase which may indicate its role in 
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regulating the cell cycle of the parasite (121).  Taken together, enzymes involved in 
signal transduction are critical for proper timing and regulation of the Plasmodium cell 
cycle in its erythrocytic stages.    
 Signaling pathways and host cell adaptation.  During the erythrocytic cycle in 
the host, P. falciparum invades the RBC, reorganizes the host cell, and exports its 
proteins to the RBC and extracellular environment in order to survive. For a merozoite 
to invade a RBC, two events must occur; the reorganization of the RBC cytoskeleton 
and the formation of the parasite invasion machinery, the glideosome complex (22, 39, 
98).  After the merozoite invades the RBC, it continues to modify the host environment 
through protein export (described above).  Exported proteins include kinases, 
phosphatases, and phosphoproteins of parasite origin. 
 First, a rearrangement of the erythrocyte cytoskeleton must occur such that it 
increases the permeability of the cell.  During this process both erythrocytic and parasite 
proteins undergo differential phosphorylation (90).  In an uninfected RBC, band 4.1 
associates with spectrin lending to the structural integrity of the RBC and β-spectrin 
contributes to the overall stability of the RBC cytoskeleton (53).  When an RBC comes 
into contact with a P. falciparum merozoite, both band 4.1 and β-spectrin are 
phosphorylated, which reduces cytoskeleton association and stability (35, 47).  Other 
RBC proteins such as ankyrin and actin may also be modified and lead to increased 
susceptibility of the host cell to the invading merozoite (126).  After invasion, parasite 
phosphoproteins can interact with both band 4.1 and spectrin, namely MESA and 
KAHRP, to further stabilize the host cell and allow for protein trafficking.   
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 Secondly, to invade the RBC, the merozoite must form the necessary invasion 
machinery.  This invasion machinery is referred to as the glideosome complex in 
Apicomplexan parasites.  The glideosome forms through the phosphorylation-
dependent association of PfGAP45, PfGAP50, PfMyoA, and PfMTIP in the outer 
membrane of the parasite [66,71,(56).  Specifically, PfGAP45 post-translational 
modification is necessary for this formation and has shown to be at least partially 
dependent on serine/threonine kinase activity (67).   Furthermore, both PfGAP45 and 
MTIP have been shown to be phosphorylated by CDPK1 (56) but the function of this 
phosphorylation is not yet known.  Therefore, phosphorylation events are critical for the 
parasite entry into the RBC where it can survive and reproduce as an intracellular 
parasite.   
 During infection by P. falciparum, the RBC undergoes phosphorylation patterns 
different than that of an uninfected cell which may play a role in intracellular survival of 
the parasite and pathogenesis.  Phosphorylation has been implicated in cytoadherence 
in many studies but its exact role has not been elucidated (60, 61, 81, 130).  
Specifically, reports have demonstrated that proteins associated with this interaction are 
phosphorylated during the adherence such as RBC protein CD36 (60), and parasite 
proteins PfEMP1 and KAHRP (81).  In addition the interaction of KAHRP with spectrin in 
the RBC cytoplasm has been shown to be phosphorylation dependent.  At least one 
kinase was implicated in this process, casein kinase II, for its role in phosphorylation of 
PfEMP1 (61).  Recent studies have attempted to analyze the differential regulation of 
phosphorylation in strains with different cytoadherent properties but have failed to find a 
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direct connection (130). Other exported proteins are involved in phosphorylation and 
host cell remodeling such as the PHIST and FIKK kinase family as mentioned above.   
 
Mitogen-Activated Protein Kinase Pathway  
 The mitogen activated protein kinase (MAPK) pathway is found in eukaryotic 
cells and allows a cell to sense its external environment and respond to stimuli.  The 
MAPK pathway is responsible for many cellular changes within the cell such as 
proliferation, differentiation, growth, and adhesion (32).  The MAPK pathway utilizes a 
phosphorylation cascade to transmit external stimuli through a cell to affect transcription 
and expression of proteins within the cell.  In this pathway, there is a tiered level of 
kinases where a membrane-bound tyrosine kinase receptor (ex. Insulin receptor or 
EGRF) recognizes the initial external signal and transmits it across the cell membrane 
to a MAPK kinase kinase (MAPKKK), which phosphorylates a MAPK kinase (MAPKK), 
and in turn phosphorylates a MAPK.  MAPKs are phosphorylated within their active 
pocket on the conserved motif TXY where both the Thr and the Tyr need to be 
phosphorylated in order to activate the kinase. If a MAPK auto-phosphorylates the Tyr 
without the activation of the MAPKK, off-target substrates may be phosphorylated.  
When a MAPK is properly activated, it is shuttled into the nucleus where it interacts with 
transcription factors to change transcription within a cell.  A MAPK can be deactivated 
through dephosphorylation of the TXY motif dependent on a MAPK phosphatase (MKP) 
in either the cytoplasm or nucleus of a cell. 
 The MAPK pathway has been identified in eukaryotes from yeast to humans and 
is thought to originate from a common progenitor cell (32).  Currently, the existence of 
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the MAPK pathway in parasitic protozoan is debated however homologues to MAPK 
proteins are present in all species (Table 1.1).  In addition, the predicted effects of the 
MAPK pathway exist in mutant parasite lines where MAPK homologues are knocked 
out.   Human parasites from the order Kinetoplastida have large MAPK repertoires such 
as Leishmania and Trypanosoma.  Apicomplexan parasites such as Toxoplasma gondii 
and Cryptosporidium parvum (not shown (17) possess three MAPK homologues while 
P. falciparum has only two identified MAPKs.  Other proteins in the pathway are putative 
and more work is needed to definitively place them in the MAPK pathway, ex. PfYVH1 
(Table 1.1). 
  
 P. falciparum MAPK Pathway 
 In P. falciparum, the lack of tyrosine and STE kinases has led to the conclusion 
that the MAPK pathway is not fully functioning in the parasite (123).  However, there are 
other kinases in the P. falciparum genome that can act as regulators of MAPKs (Table 
2).  In vitro studies have suggested that Pfnek kinases can act as MAPKKs to activate 
MAPKs and the presence of PfTKLs (tyrosine kinase-like) kinases indicate their 
potential role as MAPKKKs.  To date, there is still no receptor protein that has been 
identified as able to transduce the signal across the parasite membrane but more study 
is needed in this area.  The two MAPKs in the genome have been characterized and 
are described in the next section.  P. falciparum has 2 genes indicative of MAPK 
phosphatases (MKPs) and recently a third has been described (18).   
 P. falciparum MAPKs.  Both MAPKs in the P. falciparum genome are 
considered atypical due to their divergent sequences but both kinases retain kinase 
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activity (43, 55).  Pfmap1 has a typical kinase domain with the canonical TXY motif 
however there is a large c-terminal extension characterized by acidic residues (42, 55, 
78).  Pfmap2 is atypical in that it does not resemble a MAPK and does not have the 
TXY motif (45).  Instead it contains a TSH motif that has been shown to be critical for its 
activity where the Thr residue can be phosphorylated by Pfnek-1 and Pfnek-3 in order to 
activate the enzyme (46, 79).  Pfmap2 is a low expressing protein but has been shown 
to be critical for erythrocytic growth in P. falciparum and essential for male 
gametogenesis in P. berghei (43, 100, 116).  The function of Pfmap1 is still elusive as it 
can be knocked out in blood-stage culture with no observable phenotype (43).  There 
are also no known kinase activators of Pfmap1 as those tested so far have shown 
specificity to Pfmap2 (79, 80).   
 Pfmap2 is implicated in gametocytogenesis and is thought to be part of a 
signaling pathway that is stimulated by environmental changes that occur when the 
parasite moves from the human host to the mosquito including temperature change and 
the presence of xanthurenic acid (72).  Both of these signals are thought to stimulate 
phosphoinositol or cGMP pathways that activate an upstream calcium-dependent 
protein kinase (CDPK4) which may in turn activate Pfmap2 in order for exflagellation to 
occur.  This proposed pathway is a hint to the presence of the MAPK pathway but 
shows that it may interact with other pathways and itself be incomplete in P. falciparum.   
 P. falciparum MKPs.  P. falciparum has two identified MKPs in its genome 
which are classified as type I due to the presence of a single dual-specificity 
phosphatase (DUSP) domain (Fig. 1.2).  Only one of these phosphatases has been 
studied.  PfYVH1 was shown to have zinc-dependent phosphatase activity and the 
20 
 
ability to translocate between the nucleus and cytoplasm of the parasite where it can 
interact with other proteins in the nucleus (Table 1.2) (73).  These characteristics 
coincide with those of known MKPs in other organisms although PfYVH1 has not yet 
been studied in the context of this pathway.  Recently, another putative phosphatase 
was identified as a MKP matching the type II domain structure (Fig. 1.2) where there is 
an inactive rhodanese domain followed by a DUSP domain in tandem (18).  In type II 
MKPs, the inactive rhodanese domain can act as a MAPK binding domain (MKB) if it 
contains a signature kinase interaction motif (31).  PfMKP1 was shown to play a role in 
cell cycle regulation where it was critical for progression of the parasite into the DNA 
synthesis phase (18).  This function is in alignment with the function of MAPK pathways 
in other organisms and indicates that a functioning MAPK pathway may exist in P. 
falciparum.        
  
Genetic Manipulation of P. falciparum 
 Techniques for genetic manipulation of Plasmodium falciparum remain tedious 
and unreliable.  Double homologous recombination is the standard technique used in 
reverse genetic studies (70, 71).  However, some genes are not amenable to genetic 
ablation and therefore cannot be studied in this method (43).  Advances have been 
made in the genetic manipulation of P. falciparum including the use of zinc-finger 
nucleases and other site-specific integration techniques; however, the relative cost of 
these methods is high and the methods are still time consuming as only one gene is 
targeted (6, 113).  Recently, protein destabilization domains have been utilized to study 
genes thought to be essential to the parasite life cycle (15). 
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 An alternative to P. falciparum genetic manipulation is to use P. berghei as a 
surrogate due to its ease in genetic manipulation.  However, some important biological 
distinctions remain between P. falciparum and P. berghei.  For example, P. falciparum 
contains proteins to which there is no homologue found in P. berghei (PlasmoDB).  In 
addition, there is an expansion of certain protein families in P. falciparum that may be 
linked to the pathogenesis of the organism.  For example, the FIKK family of kinases 
are largely expanded in P. falciparum compared to P. berghei and are actively exported 
to the RBC cytosol where they may affect cytoadherence (91).  Other proteins and 
pathways may differ due to the biology of the host for which each species is specifically 
suited for (43, 116).   
  
 piggyBac Random Transposon Mutagenesis  
 Random transposon mutagenesis is a quick and efficient way to make a library of 
mutant lines that ideally saturate the genome and allow for identification of essential 
genes.  This technique has successfully been applied in P. falciparum where the 
piggyBac transposable element was used to create a library of genetic mutants from the 
wild type NF54 strain (19).  These mutant parasite lines allow for screening in 
phenotypic studies to assign functions to genes that have only hypothetical or putative 
protein status.  Previously, piggyBac mutant libraries have been used to identify genes 
critical to intra-erythrocytic growth and to gametogenesis (20, 63).   In this work, we 
continue to screen a P. falciparum piggyBac mutant library for novel phenotypes leading 
to the elucidation of the function of unidentified genes.   
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Goals of Current Work 
 The goals of the work presented here within were to develop a scalable screen 
for the phenotypic study of a piggyBac generated P. falciparum mutant library to look for 
genes involved in cytoadherence of the parasite.  In addition, PfMKP1, which was 
initially identified through the piggyBac random mutagenesis project and categorized as 
an atypical-MAPK phosphatase, was further characterized for catalytic activity and 
substrate specificity.  Lastly, to continue the study of the MAPK pathway in P. 
falciparum and look for stimuli of this pathway, a multiple reaction monitoring assay was 
developed for future implementation.   
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Figure 1.1: Life Cycle of Plasmodium Species.  An Anopheles mosquito is the vector 
for Plasmodium infections.  The erythrocytic cycle (B) is the pathogenic stage in the 
host and the focus of this work.   
Figure taken from http://www.cdc.gov/dpdx/malaria/index.html.  
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Table 1.1: Mitogen Activated Protein Kinase (MAPK) Proteins in Representative 
Parasitic Protozoan.    
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 Table 1.2: Putative Enzymes in the MAPK Pathway in P. falciparum.   
Gene name PlasmoDB ID In vitro activity  
Putative role in 
MAPK pathway 
Putative 
substrate Role in life cycle References 
Pfnek-3 PF3D7_1201600 phosphorylation MAPKK Pfmap2 asexual reproduction (80) 
Pfnek-1 PF3D7_1228300 phosphorylation MAPKK Pfmap2 asexual reproduction (44, 46) 
PfTKL-1 PF3D7_0211700 ND TGFβ receptor ND ND (123) 
PfTKL-2 PF3D7_1121300 phosphorylation unknown ND 
host 
immunomodulatory (5) 
PfTKL-3 PF3D7_1349300 phosphorylation MAPKKK ND asexual growth  (4, 14) 
PfTKL-4 PF3D7_0623800 ND MAPKKK ND ND (14, 123) 
Pfmap1 PF3D7_1431500 phosphorylation MAPK ND ND (42, 55) 
Pfmap2 PF3D7_1113900 phosphorylation MAPK ND 
erythrocytic stages; 
male gametogenesis (44, 116) 
PfYVH1 PF3D7_0309000 dephosphorylation MKP Pescadillo parasite development (73) 
PF3D7_020310
0 PF3D7_0203100 ND MAPKK ND ND (14) 
PF3D7_145510
0 PF3D7_1455100 ND MKP ND ND (127) 
PfMKP1 PF3D7_1305500 dephosphorylation MKP Pfmap1 
protein export, cell 
cycle 
This report 
(18) 
PF3D7_110680
0 PF3D7_1106800 ND Raf kinase ND ND (14) 
PF3D7_101300
0 PF3D7_1013000 ND TNFR ND ND PlasmoDB* 
Pfnek-2 PF3D7_0525900 phosphorylation ND ND sexual (102) 
PfNEK-4 PF3D7_0719200 None ND ND sexual (101) 
 PlasmoDB ID (PlasmoDB: a functional genomic database for malaria parasites; plasmodb.org/plasma; v.11.0)  
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Figure 1.2: Classification of MAPK Phosphatases (MKP).   NT = N-Terminal domain, 
MKB = MAPK Binding domain, DUSP = Dual-Specificity Phosphatase domain, PEST = 
Proline, Glutamine (E), Serine, Threonine rich domain.  Adapted from (50). 
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CHAPTER TWO: 
A SCALABLE PHENOTYPIC SCREEN OF PIGGYBAC PLASMODIUM FLACIPARUM 
MUTANTS REVEALS A ROLE FOR AN ATYPICAL MAPK PHOSPHATASE IN 
CYTOADHERENCE 
 
Introduction 
 Malaria is a deadly parasitic disease and is responsible for an estimated 660,000 
deaths worldwide (1).  Of the 5 species that cause human malaria, Plasmodium 
falciparum is responsible for almost all deaths due to severe malaria. The pathogenesis 
of severe malaria involves severe anemia, pulmonary edema, and renal failure due to 
high parasite loads in the blood and cerebral malaria due to parasite sequestration (see 
review (48)).  Parasite sequestration in tissues occurs through cytoadherence of the P. 
falciparum-infected red blood cells (iRBC) to host endothelial cells, uninfected RBCs, or 
platelets. This process is also important for evasion of splenic clearance and the 
immune system which allows the parasite to survive undetected in the host (48).   
 To catalyze sequestration, the parasite exports a large number of proteins into 
the RBC cytosol and onto the RBC surface.  Some of the most well-studied exported 
proteins, such as PfEMP1, PfEMP3 and KAHRP, form complexes at the RBC 
membrane called knobs, structures that play a key role in sequestration (33). PfEMP1 
protrudes from the knobs and is directly responsible for interacting with and adhering to 
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host cell receptors (e.g. CD36, ICAM-1, etc.); consequently when there is no PfEMP1 
surface expression, cytoadherence is greatly diminished (26).  KAHRP and PfEMP3 by 
contrast do not contact host cell receptors directly, but form part of the knob structure. 
Disruption of either gene reduces display of PfEMP1 at the knob surface and therefore 
also affects cytoadherence (11, 40, 50).  A few proteins have been relatively well 
characterized including the pathways that facilitate and control knob formation, such as 
transcriptional regulation of exported proteins, protein export, and RBC cytoskeleton 
rearrangement and stabilization.      
 In order for proteins to be effectively exported from the parasite to the RBC, 
many processes must occur.  First, the protein must be transcribed and expressed 
during the ring stage ready for export during the later stages.  Some exported proteins 
are multiple gene families where transcription is tightly regulated, ex. var genes and 
PfEMP1 proteins (43).  Second, the protein must be exported through the proper 
channels in order to localize properly in the RBC cytosol, i.e. PEXEL vs non-PEXEL 
translocation (7, 15).  Thirdly, the protein must undergo post-translational modification 
and/or be able to interact with partner proteins in the RBC cytosol to stabilize the newly 
transformed host cytoskeleton, ex. PHIST proteins regulate cytoskeleton binding 
through phosphorylation-dependent mechanisms (8, 36).  While these steps are known 
to be important for the export and stabilization of parasite proteins in the host, many 
proteins critical for these interactions remain unknown. 
       Further exploration of the mechanisms involved in protein export and 
cytoskeleton rearrangement of the RBC is important for drug discovery as this is a 
unique attribute of the parasite and paramount for the parasite’s survival within the host.  
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These mechanisms also contribute to cytoadherence which causes severe disease in 
the host.  In this work, we have developed a scalable method for determining 
cytoadherence to human receptor proteins (CD36) trans-expressed in Chinese Hamster 
Ovary (CHO) cells.  We applied this method to a library of P. falciparum mutants with 
random piggyBac insertions in or near genes, many of which have no homologues in 
other eukaryotes (5). The piggyBac system is a powerful tool to study gene function, 
and this work represents its first application to the study of cytoadherence. The screen 
identified several novel genes that impact cytoadherence, including an atypical MAPK 
phosphatase where transposon insertion into the coding sequence, disrupting gene 
function, conferred an increase in cytoadherence due to an increase in knobs on the 
surface of the iRBCs.   
 
Materials and Methods 
  
 Parasite Culture   
 Plasmodium falciparum NF54 piggyBac mutants were previously made in the 
course of a whole genome random mutagenesis project (5).  Briefly, mature blood-stage 
parasites were purified on a MACS magnetic column (Miltenyi Biotec) and 1 million 
purified parasites were added to erythrocytes loaded with 100 μg of a plasmid 
containing the piggyBac transposon with human DHFR gene flanked with P. falciparum 
UTRs and 50 μg of the transposase plasmid to start a 5 ml parasite culture. Individual 
mutant clones were obtained by limiting dilution of parasites post-drug selection.  All 
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insertion sites were identified as described (5) (Table 2.1).  The complemented 
piggyBac mutant (C9 complement) was made previously (4).   
 All cultures were maintained using standard techniques.  Plasmodium falciparum 
wild-type NF54 and the mutant clones were cultured according to standard methods at 
37°C and gassing (5% O2 and 5% CO2, nitrogen balanced) with 5% hematocrit (O+ 
blood, Interstate Blood Bank) in RPMI 1640 medium (Invitrogen) supplemented with 
0.5% Albumax II (Invitrogen), 0.25% sodium bicarbonate and 0.01 mg/ml gentamicin. 
The complemented piggyBac mutant was maintained with 2 μg/ml Blastocidin-D to 
maintain the episome.  Parasite lines were kept in culture for no longer than 3 months 
as to keep the integrity of the transposon insertion and minimize antigenic variation.   
For assays, parasite lines were synchronized during ring stage a minimum of 2x using 
5% sorbitol unless otherwise stated. 
  
 Chinese Hamster Ovary (CHO) Cell Culture 
 PsgA-745 Chinese hamster ovary (CHO745) cells deficient in glycosaminoglycans 
(American Type Culture Collection) and CHO745 transfected with CD36-expressing 
plasmid were gifts from Artur Scherf at the Institut Pasteur (19). All CHO cells were 
cultured in accordance with ATCC recommendations using RPMI (with hypoxanthine 
and HEPES) with 10% fetal calf serum and 1% Pen Strep (Gibco).   
  
 CHO Cell CD36 Expression 
 CHO cells were tested for the expression of CD36 receptor by western blot.  
CHO cells were trypsinized (Trypsin-EDTA, Cellgro) in flask and resuspended in RPMI.  
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Cells were counted with a hemocytometer and equalized to 1 x 105 cells/ml.  Cells were 
pelleted from 1 ml of suspension and resuspended in SDS-PAGE buffer with 100 mM 
DTT.  Lysates were run on a 10% SDS-PAGE gel and transferred to nitrocellulose.  
After blocking for 1 hour in 5% skim milk, Rabbit anti-CD36 (Pierce Thermo Scientific) 
1:1000 in PBS-Tween 20 and 5% skim milk was incubated with the blot overnight at 4° 
C.  The blot was washed 3x with PBS-Tween 20 and incubated with Goat anti-rabbit 
HRP conjugated antibody (Jackson Laboratories) for 1 hour followed by washing with 
PBS Tween 20 3x.  ECL reagent (GE Healthcare) was added and the blot was imaged 
on an x-ray developer (Konica Minolta SRX-101A).   
  
 Cytoadherence Assays   
 CHO745 and CHOCD36 cells were seeded into a 96-well plate 4 days prior to the 
assay at 1 x 104 cells per well in CHO cell media in order to allow for adherence and 
proper confluence.  Media was changed every day until assay and plates were kept at 
37°C with 5% CO2. 
 Parasite cultures were synchronized and grown to 2-5% parasitemia.  Parasite 
cultures were harvested in late trophozoites stages (24-30 p.i.) by gel flotation.  Briefly, 
RBCs were pelleted by centrifugation at 2426 x g for 3 min.  Plasmagel (25 ml 1M 
HEPES, 2 g CaCl2, 7.5g NaCl, 30g powdered gelatin, 900 ml di water) and RPMI was 
added to the RBC pellet and the mixture was incubated at 37° C in a water bath for 20 
min.  After separation occurred, the top layer was removed and washed in RPMI.  Cells 
were counted on a hemocytometer and all cultures were adjusted to 1x107 cells/ml.  
One hundred μl of suspension was added to each well of the seeded CHO cell plate. 
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The plate with CHO cells and purified iRBCs was incubated at 37° C for 1 hour with 
agitation every 15 minutes.  The plate was then washed with RPMI a minimum of 5x 
and fixed with 2% paraformaldehyde in RPMI for a minimum of 30 minute or overnight 
at 4° C.  After fixation, the plate was washed with PBS and the cells were stained with 
10 μg/ml Hoechst 33342 and APC mouse anti-Human CD235a (BD Pharmingen) 
1:4000 dilution in PBS for 20 minutes in the dark.  For visualization of CD36, Rabbit 
anti-CD36 was added at a 1:1000 dilution.  The plate was washed 2x with PBS and left 
in PBS for visualization.  
 
 Visualization and Counting of Cytoadherence Assays   
 After fixation and staining of cells, 96-well plates were imaged using the 
Operetta® High Content Imaging System (PerkinElmer) in wide field fluorescence mode 
using the 20X high NA objective. Twenty-five fields per well were imaged and analyzed.  
A customized algorithm by Harmony® Software (Perkin Elmer) was used to count CHO 
cell nuclei based on Hoechst 33342 staining and determine cytoplasmic area based on 
nuclei staining (Fig. 2.1C-F).  Only iRBCs within the border of the CHO cell cytoplasm 
were counted and the output was in iRBC per CHO cell.  The following equation was 
used to define fold change in cytoadherence: 
∆Fc = 3√((xCD36 – x745)/(wtCD36 – wt745)) -1 
where x is the piggyBac mutant line being tested and wt is NF54 parental line.   
Mutant lines were determined to be decreased or increased in cytoadherence if they 
were statistically significantly different than the wild-type in a one-way ANOVA followed 
by Dunnett’s multiple comparison test (GraphPad Software, La Jolla California USA).   
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 RNA Isolation, cDNA Synthesis, and Quantitative Reverse Transcription 
(qRT)-PCR 
 RNA was isolated and purified using a TRIzol reagent and following 
manufacturer’s directions (Invitrogen). First-strand cDNA was synthesized by random 
primer mixes using Superscript III Reverse Transcriptase (Life Technologies) according 
to the product manual. PCR primers used for detecting mRNA expression of var genes 
were as described previously (41).  qPCR was performed on a Stratagene Mx300P.  
The relative standard curve method (ABI User Bulletin #2) was used where genomic 
DNA was used in a standard curve to determine relative copy number and a 
housekeeping gene seryl-tRNA synthetase (PF3D7_0717700) was used to normalize 
the transcriptional level of each var gene.   
 
 P. falciparum PfMKP1 Antibody  
 Custom monoclonal antibodies to PfMKP1 were made by Abmart (Shanghai, 
China).  Briefly, peptide KNNENKQSSKNE was over-expressed in E.coli, and purified 
by Ni-affinity chromatography. Three 8 to 12-week old BALB/C mice (female) were 
immunized with the peptides and the mouse with the best immune response was 
chosen for hybridoma production.  The mouse spleen cells were fused with SP2/0 
myeloma cells to generate the hybridomas. This mixture of cells was then diluted and 
clones were grown from single parent cells on microtiter wells in HAT medium.  The 
hybridoma clones, selected for their ability to bind antigen in an ELISA, were injected in 
the peritoneal cavity of mice.  After 10-14 days, ascites fluid from tumors were collected 
and screened in western blot against mixed-stage parasite cultures.   
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 P. falciparum Protein Extraction and Western Blot 
 Parasite culture was synchronized twice with 5% sorbitol and parasites were 
harvested 5 hours later for ring stage and 28 hours later for trophozoites stage.  All 
parasites were harvested by incubating with PBS with 0.1% saponin in order to lyse 
RBCs.  Cells were washed 3x to remove RBC debris and the resulting parasite pellet 
was resuspended in SDS-PAGE buffer.  For ring stage parasites, parasitemia was 
equalized to 5% between cultures.  For trophozoites stages, culture was harvested and 
iRBCs were purified through MACS magnetic column (Miltenyi Biotec).  The purified 
iRBCs were counted by hemocytometer and adjusted to 1 x 10^7 cells/ml to standardize 
the number of iRBC across strains.    Samples were loaded onto a gradient SDS-PAGE 
gel and western blot was conducted in the same manner as stated above using Mouse 
anti-PyBiP (a gift from Sebastian Mikolajczak, unpublished) at 1:1000 and Rabbit anti-
EXP2 (a gift from Paul Gilsen) at 1:5000 or anti-PfMKP1 at 1:1000.  Secondary HRP 
conjugated goat anti-rabbit or anti-mouse (Jackson Laboratories) was used at a 
1:10,000 dilution. 
 
 Surface PfEMP1 Expression 
 Surface expression of PfEMP1 was determined using the methods of Spycher et 
al. (45).  Briefly, parasites were synchronized by sorbitol twice 4 hours apart, grown to 
trophozoite stage (20–28 h post invasion) at a parasitemia of approximately 5%, and 
harvested by magnet column (CS columns; Miltenyi Biotec). Infected RBCs were 
equalized between strains to 1 x 10^7 cells and either treated with TPCK-treated trypsin 
(Sigma) 1 mg/ml or incubated in PBS for 10 min at 37°C. The reaction was stopped with 
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protease inhibitor cocktail (Invitrogen) and the sample was pelleted and solubilized in 
1% Triton-X 100.  The insoluble pellet was resuspended in 2% SDS buffer, loaded onto 
a gradient Tris-Glycine gel and subjected to SDS-PAGE. The proteins were transferred 
onto nitrocellulose (Hybond-C Extra, Amersham Biosciences), and the blot was probed 
with guinea pig anti-ATS antibody (1:500) [a gift from Denise Mattei] for PfEMP1 
detection.  Blots were incubated with alkaline phosphatase-conjugated guinea pig 
secondary antibody (Pierce, 1:4000) and developed with BCIP/NBT solution (Sigma). 
  
 Immunoflourescence Assay (IFA) 
 Parasites were synchronized as stated above and immunofluorescence assays 
were done as previously described (20). Blood films were double-stained with Rabbit 
anti-Pf332 mAb51-22 diluted 1:500 followed by FITC-conjugated Goat anti-rabbit 
secondary and Mouse anti-KAHRP mAb89 diluted 1:800 followed by Alexaflour 594 
conjugated goat anti-mouse secondary (anti-Pf332 and anti-KAHRP were kind gifts of 
Denise Mattei).  Nuclei were stained with 0.2 mg/ml 4′, 6-diamidino-2-phenylindole 
(DAPI; Molecular Probes). Parasites were visualized by a DeltaVision CORE 
microscope (Applied Precision).   
  
 Scanning Electron Microscopy (SEM) 
 SEM was performed with trophozoite (24-28 hours) iRBCs purified by magnetic 
columns (CS columns; Miltenyi Biotec) followed by fixation (1% paraformaldehyde and 
0.2% glutaraldehyde in HEPES buffer) for 30 minutes on ice. Cells were washed 3x in 
HEPES buffer and stored at 4° C.  The cells were post-fixed with 1% osmium tetroxide 
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followed by rinsing with water and dehydration in a graded ethanol series (10%, 35%, 
70%, 100%; 5 minutes each). Cells were subjected to chemical drying (HMDS), coated 
with gold and palladium in a sputter coater, and viewed in a JEOL JSM6490 Scanning 
Electron Microscope at 6 kV.  
 The number of knobs on the surface of the iRBCs (20 per cell line) was counted 
using ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2012).   To determine 
statistical significance, a one-way ANOVA followed by Tukey’s multiple comparisons 
test was performed using GraphPad Prism v. 6 (GraphPad Software, La Jolla California 
USA).  
 
 2D- Differential Gel Electrophoresis (DIGE)   
 Parasite cultures were synchronized 2x and harvested in late trophozoite stage 
followed by purification on a magnetic column and saponin lysis. Two-Dimensional 
DIGE and Protein ID was performed by Applied Biomics, Inc (Hayward, CA). Briefly, 
after phosphostaining, the spots of interest were picked up by an Ettan Spot Picker 
(Amersham BioSciences) based on the in-gel analysis and spot picking design by 
DeCyder software. The gel spots were washed a few times then digested in-gel with 
modified porcine trypsin protease (Trypsin Gold, Promega). The digested tryptic 
peptides were desalted by Zip-tip C18 (Millipore). Peptides were eluted from the Zip-tip 
with 0.5 ul of matrix solution α-cyano-4-hydroxycinnamic acid (5 mg/ml in 50% 
acetonitrile, 0.1% trifluoroacetic acid, 25 mM ammonium bicarbonate) and spotted on 
the MALDI plate (model ABI 01-192-6-AB).  MALDI-TOF MS and TOF/TOF tandem 
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MS/MS were performed on an ABI 4700 mass spectrometer (Applied Biosystems, 
Framingham, MA). Both the resulting peptide mass and the associated fragmentation 
spectra were submitted to GPS Explorer workstation equipped with MASCOT search 
engine (Matrix science) to search the database of National Center for Biotechnology 
Information non-redundant (NCBInr).  Searches were performed without constraining 
protein molecular weight or isoelectric point, with variable carbamidomethylation of 
cysteine and oxidation of methionine residues, and with one missed cleavage also 
allowed in the search parameters. Candidates with either protein score C.I.% or Ion 
C.I.% greater than 95 were considered significant. 
 
  Immunoelectron Microscopy (IEM)    
 P. falciparum-infected erythrocytes were fixed for 30 min on ice in a mixture of 
1% paraformaldehyde–0.2% glutaraldehyde in HEPES buffered saline. Fixed 
specimens were washed, dehydrated, and embedded in LR-White resin (Polysciences, 
Warrington, PA). Ultrathin sections on nickel grids were blocked for 30 min in PBS 
containing 5% nonfat milk and 0.01%Tween 20 (PBS-Milk-Tween), incubated overnight 
at 4°C in PBS-Milk-Tween containing rabbit anti-Pf-EXP2 serum (1/50 dilution), and 
then incubated at 37°C for 1 h in PBS-Milk-Tween containing goat anti-rabbit IgG 
conjugated with gold particles (15 nm diameter, British BioCell International, UK) at 1/20 
dilution. Sections were examined with a JEM-1230 electron microscope (JEOL, Japan) 
after staining with 2 % uranyl acetate and lead citrate. 
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Results 
  
 Development of piggyBac Cytoadherence Screen Using Operetta® High 
Content Screening  
 P. falciparum piggyBac mutant lines were tested for cytoadherence to receptor 
CD36 expressed in CHO745 cells using a scaled format and auto-visualization on the 
Operetta® High Content Screening System (HCS). Most P. falciparum strains bind to 
CD36 receptor including NF54 used in this study.  CHOCD36 and CHO745 (the wild-type 
CHO cell line from which CHOCD36 was generated) were tested for relative amounts of 
CD36 expression on the surface of the cell using a commercial anti-CD36 antibody. 
CHOCD36 expresses an increased amount as expected due to the stable transfection of 
an expression plasmid containing the gene for CD36, as previously described (19) (Fig. 
2.1A).  Visualization of CHO745 and CHOCD36 cells with anti-CD36 staining showed no 
expression of CD36 (or below detection) on the surface of the cytoplasm of CHO745 (not 
shown) while CHOCD36 had surface expression of CD36, as expected (Fig. 2.1B). 
 In order to increase the throughput of screening for cytoadherence, we modified 
previous approaches in order to utilize the Operetta® HCS, which allows for automation 
of many aspects of the assay. CHO cell nuclei were stained with Hoechst and iRBCs 
were stained with anti-glycophorin A and visualized at 20x (Fig. 2.1C).  The nuclei of 
CHO cells were detected (Fig. 2.1D) and the cytoplasm (Fig. 2.1E) of the CHO cells 
was defined based on the nuclei using Harmony® Software preset algorithms.  
Glycophorin A-stained iRBCs were counted as attached to CHO cells if they were at 
least 50% within the borders of the CHO cell cytoplasm (Fig. 2.1F).  In order to validate 
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this method as quantitative, purified P. falciparum NF54 iRBCs were incubated with 
CHOCD36 cells at 10-fold dilutions from 10^8 iRBCs/ml to 10^4 iRBCs/ml (Fig. 2.2).  
There was a high positive correlation between parasitemia and ∆Fc (fold change in 
cytoadherence; as described in methods) with an R2 of 0.9845 (Fig. 2.2A).  
Furthermore, the standard deviation in the dilution range of 10-10,000 was minimal and 
could determine differences in binding (Fig. 2.2B). This value was therefore selected for 
subsequent screening.  
 
 P. falciparum piggyBac Mutant Cytoadherence Screen  
 Thirty-four randomly chosen P. falciparum piggyBac lines from a mutant library of 
P. falciparum lines were tested for cytoadherence.  piggyBac insertions were first 
identified by tail PCR for transposon insertion (5) and in some cases the insertion site 
was confirmed by whole genome sequencing (WGS) or transposon-directed insertion 
site sequencing (TraDIS) (Supp. Table; manuscript in preparation). P. falciparum NF54 
wild type and mutant lines were equalized in parasitemia and life cycle stage before 
being allowed to bind to CHO745 and CHOCD36.  Background binding was accounted for 
by subtracting the average number of iRBCs that bound to CHO745 cells from the 
number of iRBCs binding to CHOCD36. To determine the rate at which the mutant line 
bound compared to NF54, the number of iRBCs binding to CD36 was divided by the 
number of NF54 iRBCs binding to CD36 and transformed in order to normalize and 
compare cytoadherence across experiments (see Methods). During the course of the 
experiments, wild-type NF54 was used as a control in all cytoadherence assays and 
after transformation set to zero for individual experiments.  Mutants were considered 
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decreased or increased in cytoadherence if the mean binding to CHOCD36 varied 
significantly from the mean binding of NF54 (fold change equal to zero) as tested by a 
one-way ANOVA followed by Dunnett’s multiple comparisons test.   
Many mutants (47%) did not show a significant difference in binding phenotype 
from the wild type NF54 strain (Fig. 2.3, 2.4, and Table 2.1).  Twelve of the 34 mutants 
tested exhibited a decrease in binding while only 6 showed an increase in binding to 
CD36 (Fig. 2.3).  Mutants were categorized by the assigned gene ontology (GO) based 
on the ORF which the transposon disrupted.  All GO categories were found in the 
mutants exhibiting no difference in cytoadherence, while the GO categories protein 
modification and nucleic acid metabolism were enriched in both the decreased and 
increased mutant groups (Fig. 2.4). This implies that the effect on cytoadherence in 
these mutants is an indirect regulatory one, perhaps controlling PfEMP1 expression or 
export.    
  
 Antigenic Variation in piggyBac Mutants  
 The PfEMP1 surface protein is expressed by a multi-gene family of var genes 
(46), with only one var gene expressed by an individual parasite at any given time (42).  
The consequence of var gene switching in culture could result in a false change in 
cytoadherence phenotype due to the change in expression of the var gene rather than a 
genetic defect affecting cytoadherence. (42).  To test whether the piggyBac insertion 
had impacted PfEMP1 transcription, mutant lines and the NF54 control were checked 
for var gene expression through qRT-PCR. NF54 and the majority of mutant cell lines 
tested expressed var gene PF3D7_0421100, indicating there was no antigenic 
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switching between the mutant and parent cell lines during maintenance of cultures 
(Table 2.1).  Incidentally, this var gene contains the DBL domain that has been 
previously implicated in adhesion to CD36 receptors (39). Notably, a small subset of 
mutants (PF3D7_1143500, PF3D7_1133700, PF3D7_0416500) that were decreased in 
cytoadherence did not express this var gene.  Interestingly, one mutant has an insertion 
in a RNA-binding domain-containing gene (PF3D7_1133700) and another in a gene 
involved in chromatin condensation (PF3D7_1143500) which may affect var gene 
expression and therefore cause a decrease in cytoadherence.  The last mutant has a 
transposon insertion in a gene (PF3D7_0416500) upstream of the var gene that was 
expressed in the parent line, indicating that the transposon insertion could affect the 
expression of downstream genes however, further work to determine if a var gene is in 
fact being expressed needs to be determined  
  
 Absence of PfMKP1 Expression Increases Cytoadherence to CD36  
 One of the mutants (C9) that showed an increase in CD36 binding contains a 
piggyBac transposon insertion in gene PF3D7_1305500 (PfMKP1) (Fig. 2.3).  To 
establish whether the cytoadherence phenotype was directly due to insertion in the 
PfMKP1 coding sequence, the C9 mutant was complemented with an episomal copy of 
the gene PfMKP1 with its native 5’ UTR and a 3’ 3x HA tag followed by a HRP3 3’ UTR. 
RT-PCR previously confirmed that the complemented line reintroduced expression of 
PfMKP1 RNA (4), and PfMKP1 protein expression was confirmed in the wild-type strain 
NF54 and the complemented mutant by western blot using a monoclonal custom 
antibody (anti-PfMKP1), while the C9 mutant showed no expression (Fig. 2.5A).  To 
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confirm that the increase in cytoadherence was due to the loss of expression of 
PfMKP1, the CHO cell-based cytoadherence assay was performed with the PfMKP1 
complemented line.  The increase in cytoadherence in the C9 mutant at 0.31-fold 
increase over the wild type was statistically significant in a one-way ANOVA, while 
complementation of PfMKP1 fully restored the cytoadherence phenotype to wild-type 
levels (Fig. 2.5B).  To determine whether the increased binding to CD36 was due to an 
increase in nonspecific binding, rather than being CD36 specific, a purified receptor-
based adherence assay was conducted.  This assay found that both wild type NF54 and 
the C9 piggyBac mutant only adhere to CD36 and not to other receptor molecules such 
as ICAM-1 and CSA (Fig. 2.5C).  An increase in binding to CD36 by the C9 mutant line 
was also found in this different assay system, but experimental variation in this system 
made this not a statistically significant association, emphasizing the benefits of the HCS 
assay developed above.  
  
 Analysis of Knob Structures and Exported Proteins in C9 Mutant 
 In order to elucidate the mechanism for increased cytoadherence, we looked at 
expression and localization of proteins known to be involved in cytoadherence, including 
PfEMP1, KAHRP, and Maurer’s cleft proteins.  In both the wild-type and C9 mutant line, 
PfEMP1 expression was similar as determined by western blot (Fig. 2.6A).  In addition, 
using methods by Spycher et al. (45), we looked at RBC surface-exposed PfEMP1 and 
detected no significant increase in PfEMP1 on the surface of the C9 mutant iRBCs as 
compared to WT (Fig. 2.6A). Also, both the Maurer’s cleft protein Pf332 and KAHRP 
showed similar localization patterns in WT and C9 by IFA (Fig. 2.6B).  
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 While IFA (Fig. 2.6B) did not detect a significant change in the expression or 
localization of these few known exported proteins, many more proteins are exported 
than can be detected by blot or IFA. To assess gross changes in export protein 
associated structures, we used scanning electron microscopy to look at the knobs on 
the iRBC surface of the mutant, wild type, and complemented mutant.  Twenty iRBCs 
collected in late trophozoite stage were analyzed for the average number of knobs on 
the surface of the iRBC.  SEM of the iRBCs demonstrated an increase in knobs on the 
surface of the C9 mutant compared to both wild-type and complemented mutant (Fig. 
2.7A-E).  P. falciparum NF54 had an average of 8 knobs per μm2, the complemented 
mutant had an average of 10 knobs, and the C9 mutant had an average of 16 knobs. 
PfMKP1 disruption therefore clearly has a significant impact on knob formation  
  
 Global Analysis of Protein Expression in C9 Mutant   
 In order to tease out the relationship between this MAPK phosphatase and an 
increase in knobs, we compared overall protein expression (Fig. 2.8).  Two-dimensional 
differential gel electrophoresis (2D-DIGE) was conducted to compare the mutant, wild-
type, and complemented mutant protein expression.  Spots were chosen based on 
differential expression in the mutant.  Specific proteins that were overexpressed in the 
mutant included an endoplasmic reticulum-resident calcium binding protein 
(PF3D7_1108600) and two fragment proteins of merozoite surface protein 7 (MSP7; 
PF3D7_1335100) (Fig. 2.8).  In addition, exported protein 2 (EXP2; PF3D7_1471100) 
was found to be differentially expressed in two separate 2D-DIGE experiments (Fig. 
2.8).    
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 Exported Protein 2 in C9 Mutant 
 Further experiments were carried out to determine the nature of EXP2 in the C9 
mutant.  A western blot of the complemented mutant, mutant, and wild type during ring 
stages and trophozoites stages indicated no change in overall expression of EXP2 and 
its oligomer forms (Fig. 2.9A) as first described by Bullen et al. (9).  Furthermore, under 
immunoelectron microscopy, gold staining of EXP2 indicated no aberrant change in 
localization patterns as EXP2 was found in the PVM in both the wild-type and mutant 
(Fig. 2.9B).  Further attempts to pull-down EXP2 and look for post-translational 
modification changes that may contribute to the differential expression were 
unsuccessful.   
 
Discussion 
 Cytoadherence plays a critical role in malaria pathogenesis, and has been one of 
the most studied aspects of P. falciparum biology. However, the assays to measure 
cytoadherence such as purified receptor or flow-based assays have often been 
qualitative in nature and involve labor-intensive methods that cannot be scaled.  During 
the course of this work we have developed a novel scalable method for P. falciparum 
cytoadherence using High Content Screening that has a wide range of applications.  
Recently, a similar study gave proof of principle to the HCS method for use in drug 
screening of compounds that explicitly inhibit cytoadherence to cells expressing CSA 
(receptor involved in placental malaria) (27).   
Using this assay in conjunction with a library of P. falciparum piggyBac mutant 
lines, we identified several genes potentially involved in cytoadherence that have not 
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been previously described, most of which are annotated as hypothetical proteins. 
Several of the genes with cytoadherence phenotypes are involved in nucleic acid 
metabolism and protein modification, suggesting that they have a regulatory affect. 
Some of these mutants may directly affect transcription of exported proteins, such as 
PF3D7_0404100 and PF3D7_1136000 which contain insertions in putative AP2 
transcription factor genes and both exhibit a decrease in binding to CD36 compared to 
wild type.   In addition, PF3D7_0611800, which had an increase in cytoadherence, has 
an insertion in a gene that is not annotated as an AP2, but is an orthologue to genes 
that are annotated as hypothetical AP2s in other Plasmodium species.  At this time, the 
targets of these transcriptional regulators are not known but PF3D7_0404100 has been 
implicated in sexual development of the parasite (32).  At least one AP2 factor PfSIP2 
has been found to be involved in the silencing of var genes through its involvement in 
heterochromatin formation (16) and ApiAP2 binding sites have been identified upstream 
of var genes (10) signifying that AP2s may be involved in regulation of genes involved in 
cytoadherence.   
 We also found that insertional mutations in genes with putative phosphatase and 
kinase activity affect the relative cytoadherence of the iRBC.   One piggyBac mutant 
with an insertion in a P. falciparum-specific kinase, FIKK 9.3 (PF3D7_0902200), was 
found to have decreased cytoadherence properties while two mutants with insertions in 
putative phosphatase genes, PF3D7_0615900 and PF3D7_1305500, demonstrated an 
increase in cytoadherence suggesting a role for phosphorylation of proteins in 
cytoadherence.  FIKK is a multi-gene family that encodes exported kinases only found 
in Plasmodium sp.  FIKKs have been implicated in RBC rearrangement and stabilization 
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(8, 34) which further indicates a role for phosphorylation in stabilization of P. falciparum 
proteins within the RBC cytosol as a mechanism for cytoadherence. 
 We chose to further study in detail the piggyBac mutant which had an insertion in 
an atypical MAPK phosphatase gene (PfMKP1).  The loss of expression of PfMKP1 in 
the piggyBac mutant C9 increased cytoadherence and the number of knobs on the 
surface of iRBCs, although it did not directly impact the expression of KAHRP, a major 
structural component of knobs (data not shown).  KAHRP does not directly interact with 
receptors such as CD36, but knob formation is important for PfEMP1 surface 
presentation and can indirectly affect cytoadherence (25, 35, 40, 51).  We believe the 
fold-change increase in cytoadherence in the piggyBac mutant C9 is due to the increase 
in knobs on the iRBC and therefore an increase in adhesive nature. That this was a 
direct effect of PfMKP1 disruption was genetically validated by complementation of the 
mutant line with the native PfMKP1 gene.   
 Furthermore, in the 2D-DIGE analysis, an ER-resident protein and exported 
proteins (EXP2 and MSP7) were found to be differentially regulated in the mutant.  The 
ER-resident protein (PfERC; PF3D7_1108600) has been implicated in the classical 
protein export pathway in P. falciparum (2, 28) and its increase in expression may 
designate a role for PfMKP1 early in the export pathway.  In addition, both EXP2 and 
MSP7 were found to be in higher quantities in the C9 mutant.  Both these proteins are 
known to be exported to the PVM or RBC.  In this work, two separate DIGE experiments 
were carried out and both showed a difference in expression in EXP2 in the mutant as 
compared to wild-type and complemented mutant.  However, in the second DIGE 
experiment performed the change was not as significant.  In addition, follow up studies 
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on EXP2, IEM and western blot analysis, indicated no discernable change in EXP2. 
Together, this information indicates a change in the protein export pathway due to the 
loss of expression of PfMKP1.  However, the exact mechanism for the increase of 
knobs due to the loss of PfMKP1, an atypical MAPK phosphatase, remains unclear.   
 The putative substrate of PfMKP1 is a mitogen-activated protein kinase (MAPK) 
of which there is two identified in the P. falciparum genome, Pfmap1 and Pfmap2 (13, 
17, 30).  MAPK pathways are complex intracellular signaling systems which use a 
phosphorylation cascade to allow a cell to respond to the external environment.  
Although homologues of the kinases in the classical three-component system of the 
MAPK pathway are not present in P. falciparum, other putative kinases that can fulfill 
the role of the three-component system have been identified (3, 31).  Pfmap2 is an 
atypical MAPK and has been found to be necessary for P. falciparum intra-erythrocytic 
development and male gametogenesis (14, 38, 47), while a role for Pfmap1 has not 
been identified.    The involvement of the MAPK pathway in Plasmodium cytoadherence 
has yet to be studied but MAPK pathways in other organisms can lead to cell 
cytoskeleton changes and alterations in the adhesive state of the cell (18, 44).   
 Post-translational modification of proteins, specifically phosphorylation, can lead 
to changes in localization of proteins and protein-protein interactions.   Invasion of the 
RBC by P. falciparum merozoites is dependent on a protein complex that allows the 
parasite to actively invaginate the RBC (6, 24).  This complex forms through protein-
protein interactions that are dependent on phosphorylation (23).  Furthermore, the 
interaction between KAHRP and PfEMP1 at the RBC membrane was also found to be 
dependent on phosphorylation due to the action of Casein Kinase II (22).  Knobless 
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parasites were found to exhibit a different phosphorylation pattern of proteins compared 
to parasites that form knobs in iRBCs, leading to the potential of the parasite-produced 
proteins to not only affect phosphorylation within the parasite proteome, but within the 
host, also.  Within the host cell, cytoadherence of iRBCs causes changes in 
phosphorylation and CD36 receptor recruitment to the cell surface which further 
increases the strength of the binding interaction (12, 21, 52).  Other parasite proteins 
that are exported or involved in the machinery of exportation have identified 
phosphorylation sites (29, 37, 49) but the function of these sites has yet to be studied.     
 Herein, we have described a method that can be used to identify target genes 
and putative pathways for drug discovery in severe malaria.  The events leading up to 
cytoadherence of an iRBC within a host are complex and still mostly unknown.  During 
this study, we developed a novel approach for discovering new genes that may directly 
or indirectly affect cytoadherence.  We further identified the MAPK pathway in P. 
falciparum as a putative pathway that can affect protein export in P. falciparum.  Further 
work to determine the relationship between this pathway and cytoadherence could lead 
to the further elucidation of the importance of the MAPK signaling pathway in P. 
falciparum.  Because cytoadherence is an important phenomenon that causes 
pathogenesis in the host, drugs that alter this pathway may be used to treat severe 
malaria and reduce deaths due to cerebral malaria.         
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Table 2.1: Description of P. falciparum piggyBac Mutants Used in Cytoadherence Assay.   
PlasmoDB ID (plasmodb.org/plasmo/; v. 11.0)  
ND = Not determined 
WGS = Whole genome sequencing 
TraDIS = Transposon-directed insertion site sequencing
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Figure 2.1: Development of Cytoadherence Assay Using Chinese Hamster Ovary 
Cells and Operetta® High Content Screening.  Chinese Hamster Ovary (CHO) cells 
were tested for expression of the receptor CD36 by western blot (A), and by 
immunofluorescence (B) imaged by Operetta at 20x objective, Blue = Hoechst 33342 
staining of nuclei, pink = anti-CD36 staining, and the arrow indicates bound iRBCs. 
CHO cells and iRBCs were stained with Hoechst 33342 (blue=CHO nuclei) and anti-
GPA (pink=iRBC) and imaged on the Operetta at 20x (C).  Harmony® software 
algorithms determined CHO cell nuclei (D) and CHO cytoplasm (E), and Harmony® 
software counted iRBCs (pink dots) within the boundaries of the CHO cells (multi-
colored outline) (F).   
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Figure 2.2: Validation of Cytoadherence Assay using Operetta® HCS and ∆Fc 
Formula.  (A) Linear regression of NF54 binding across a series of dilutions gave a high 
R-squared value. (B) Bar chart of data obtained in 2 different experiments using 
dilutions of NF54 demonstrated increased standard deviations at both the high and low 
end of dilution spectrum. 
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Figure 2.3: Cytoadherence Screen of piggyBac Mutants. P. falciparum clone NF54 and mutants (GeneDB IDs indicate 
locus of transposon insertion) are shown on a graph according to the ∆Fc which is defined as the fold change in binding to 
CHO-CD36 cells compared to NF54 parent line.  Gray bars indicate mutants significantly increased in binding (n=6), white 
bars are not significantly different than wild-type NF54 (n=16), and black bars indicate mutants significantly decreased in 
binding (n=12).  Statistical significance was determined by one-way ANOVA at p<0.05.
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Figure 2.4: Categorization of piggyBac Mutants Tested in Cytoadherence Screen.  
(A) piggyBac mutant lines were characterized as increased (n=6), decreased (n=12), or 
no change (n=16) compared to NF54 wild-type.  (B) Gene ontology categorization of 
mutants that were decreased, exhibited no change, and increased in cytoadherence as 
compared to wild-type NF54.  Gene ontologies were based on the gene containing the 
piggyBac insertion as described in PlasmoDB product description or by protein domain 
homology to other genes.   
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Figure 2.5: Insertional Mutant of PfMKP1 (C9) Demonstrates Increased Binding to 
CD36 Receptors and is Restored to Wild-type Binding When Complemented. (A) 
Western blot of parasite lysate showing expression of PfMKP1 in wild-type and 
complemented mutant but not in mutant C9 strain, (B) Fold change in cytoadherence of 
C9 mutant and C9 complemented mutant compared to NF54 wild-type, * indicates 
statistical significance at p<0.05. (C) NF54 (WT) and insertional mutant (C9) were 
tested against purified receptors Cluster of Differentiation 36 (CD36), Intercellular 
adhesion molecule 1 (ICAM-1), and Chondroitin sulfate A (CSA). 
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Figure 2.6: Comparison of Proteins Involved in Cytoadherence between NF54 
Wild-type and C9 piggyBac Mutant. (A) Protein expression of PfEMP1 using anti-ATS 
sera.  Top panel shows only surface exposed protein and bottom panel is total PfEMP1 
in cell.  (B) Immunofluorescence of proteins involved in cytoadherence in C9 and NF54 
cell lines shows no aberrant changes in localization of common proteins in export 
pathway. Maurer’s cleft protein marker (Pf332) and knob-associated histidine rich 
protein (KAHRP) were stained with antibodies and DAPI was used for nuclei 
visualization.       
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Figure 2.7: Scanning Electron Microscopy Shows Increased Knobs on Surface of 
C9 Parasite Line.  (A) uninfected RBC, (B) NF54 iRBC, (C) C9 iRBC, (D) C9_comp 
iRBC.  (E) Statistical analysis of knobs per micron squared using a one-way ANOVA 
followed by Tukey multiple comparison test, n=20, demonstrated significant difference in 
C9 mutant compared to NF54 and C9 complement. 
  
64 
 
 
 
Figure 2.8: Changes in Proteome of C9 Mutant.  Two-dimensional gel 
electrophoresis of piggyBac mutant C9 (blue), wild type NF54 (green), and 
complemented mutant (red). White spots indicate overlapping expression between all 3 
strains.  Enlarged areas show increased expression in C9 mutant of ER-resident 
calcium binding protein (ERD), exported protein 2 (EXP2), and fragments of MSP7. (B) 
Fold increase in expression of C9 mutant over wild-type and C9 complemented mutant. 
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Figure 2.9: Evaluation of Exported Protein 2 (EXP2) in NF54, C9 Mutant, and 
Complemented Mutant Cell Lines.  There was no difference observed in overall 
expression of EXP2 by (A) Western blot analysis or localization by (B) immunoelectron 
microscopy, arrow indicates gold particle staining of EXP2 in the parasitophorous 
vacuole membrane (PVM). 
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CHAPTER THREE: 
CHARACTERIZATION OF AN ATYPICAL TYPE II MITOGEN ACTIVATED PROTEIN 
KINASE PHOSPHATASE IN PLASMODIUM FALCIPARUM 
 
Introduction 
 Plasmodium falciparum is an intracellular parasitic protozoan which causes 
pathogenesis by invading erythrocytes within the human host.  Signaling pathways 
involving phosphorylation have been studied in this parasite and found to be important 
for invasion, protein export and host cell remodeling (10, 11, 23, 31).  P. falciparum has 
~99 putative protein kinase or protein kinase-like coding genes in its genome (1, 32) 
and 27 protein phosphatase coding genes (34) as well as a minimum of 650 proteins 
with identified phosphorylation sites (26).  Based on genomic bioinformatic analysis, the 
P. falciparum kinome is similar to most eukaryotic cells but has an additional family of 
kinases not found in other genera (FIKK) and is missing homologues to tyrosine and 
STE (Sterile yeast) kinases (26, 32).  Although tyrosine kinases have not been identified 
in the genome, phosphoproteomic analysis of P. falciparum has revealed tyrosine 
phosphorylation of parasite proteins at rates similar to other eukaryotic cells (<1% of all 
phosphorylation sites) (26).  Because of the lack of STE kinase homologues in the 
genome, there are no apparent homologues to mitogen activated protein kinase kinases 
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(MAPKK) or mitogen-activated protein kinase kinase kinase (MAPKKK) and therefore it 
is unknown if the MAPK pathway functions in P. falciparum.   
 The MAPK pathway is found in eukaryotic cells and allows a cell to sense its 
external environment and respond to stimuli.  The MAPK pathway is responsible for 
many cellular changes within the cell such as proliferation, differentiation, growth, and 
adhesion (27).  The MAPK pathway utilizes a phosphorylation cascade to transmit 
external stimuli through a cell to affect transcription and expression of proteins within 
the cell (3).  In this pathway, there is a tiered level of kinases where a membrane-bound 
tyrosine kinase receptor (ex. Insulin receptor or EGRF) recognizes the initial external 
signal and transmits it across the cell membrane to a MAPKKK, which phosphorylates a 
MAPKK, and in turn phosphorylates a MAPK.  MAPKs are phosphorylated within their 
active pocket on the conserved motif TXY where both the Thr and the Tyr need to be 
phosphorylated in order to activate the kinase. If a MAPK auto-phosphorylates the Tyr 
without the activation of the MAPKK, off-target substrates may be phosphorylated.  
When a MAPK is activated, it shuttles into the nucleus where it interacts with 
transcription factors to change transcription within a cell.  A MAPK can be deactivated 
through dephosphorylation of the TXY motif dependent on a MAPK phosphatase (MKP) 
in either the cytoplasm or nucleus of a cell.   
 Within P. falciparum two MAPK homologues have been identified, Pfmap1 and 
Pfmap2 (6-8, 25, 33).  Pfmap2 is thought to be required for growth of P. falciparum 
within the red blood cell due to its inability to be knocked out (7).  In P. berghei, 
Pbmap2, the orthologue to Pfmap2, is not necessary for growth in the intra-erythrocytic 
stage but plays a role in male gametogenesis (14, 25, 29).  Pfmap2 does not have the 
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canonical TXY motif but instead a TSH motif in which phosphorylation of the Thr is 
critical for enzyme activation in vitro (8, 21).  The other identified MAPK in P. falciparum, 
Pfmap1 is not necessary for intra-erythrocytic growth of the parasite and has yet to be 
assigned a function (6, 7, 18).  This kinase does have the conserved TXY motif which 
its phosphorylation is critical for catalytic activity in vitro (12).  To date, there have been 
no identified MAPKK, MAPKKK, or tyrosine kinase receptors in P. falciparum.  However, 
kinases such as Pfnek-3 and Pfnek-1 are capable of phosphorylating MAPKs on their 
active site in vitro and may act as MAPKKs in vivo (9, 19-22).  There are 2 putative 
MAPK phosphatase (MKP) homologues in the P. falciparum genome (34), but their role 
in the MAPK pathway has yet to be demonstrated.  Both of these have sequences 
indicative of type I MKPs where there is a single dual-specificity phosphatase (DUSP) 
domain. One of these MKPs, PfYVH1 has significant homology to the human YVH1 and 
can translocate between the nucleus and cytoplasm of the parasite (16), a feature found 
in MKPs (17).      
 Recently, we have published on an atypical-MKP in the P. falciparum genome, 
PfMKP1 (2).  This MKP has a sequence structure indicative of a type II MKP with an 
inactive-rhodanese (RHD) domain followed by a DUSP domain.  It is atypical in that the 
conserved CX5R motif found in all catalytically active DUSP domains is replaced by a 
CX14I motif.  Previously, we found PfMKP1 to play a role in intra-erythrocytic growth of 
the parasite (2).  Here, we further characterize PfMKP1 by establishing its catalytic 
activity and identify its potential substrate as Pfmap1, further demonstrating evidence 
for the presence of a functioning MAPK pathway in P. falciparum.   
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Materials and Methods 
 
 Recombinant Protein Constructs   
 PfMKP1 (PF3D7_ 1305500) sequence was retrieved from PlasmoDB.  A 
truncated version (aa1-560) where the putative transmembrane domains were removed 
was used for production of a synthetic codon-optimized construct for expression in E. 
coli with an N-terminal glutathione-S transferase (GST) tag (GeneArt).  The truncated 
gene construct was subcloned into pGex-2T and transformed into E. coli DH5α (NEB) 
and E. coli BL21 (NEB) for mutagenesis and expression, respectively.  Single domain 
GST-tagged constructs, rhodanese (RHD; aa1-189) and dual-specificity phosphatase 
(DUSP; aa210-560), were also made and transformed into BL21 for expression (see 
Fig. 3.1 and Table 3.1).  GST only was produced from pGEX-2T as a control. In some 
cases, to improve expression, constructs were subcloned into pCOLDIV (TaKaRa) and 
transformed into BL21 (see Table 3.1).   
 Pfamp1 (kinase domain only)-NusA-His6 and Pfmap2-NusA-His6 constructs in 
pCOLDIV vector were supplied as a kind gift from Isabelle Lucet (Monash University).  
Both plasmids were transformed into BL21 cells for expression of protein.  Additionally, 
a construct of NusA-His6 only was made by using primers (see Table 3.1) to amplify the 
plasmid minus the Pfmap2 gene.  The plasmid was ligated and transformed into BL21 
for expression.    
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 Expression of Recombinant Proteins 
 For protein expression, 3 ml of overnight culture (in LB plus 100 μg/ml ampicillin) 
was inoculated into 1 liter (LB with 100 μg/ml ampicillin). The culture was grown to log 
phase (OD600, ∼0.4 to 0.6), and protein expression was induced by the addition of 1 
mM IPTG (isopropyl-β-D-thiogalactopyranoside).  E. coli BL21 cells containing the 
pCOLDIV expression vector for protein expression were incubated at 15°C with shaking 
for 20-24 hours.  E. coli BL21 with pGEX-2T plasmid for expression of proteins were 
incubated at room temperature (~27° C) overnight with agitation.  Bacterial cells were 
collected by centrifugation at 5,000 × g for 15 min, suspended in 25 ml lysis buffer 
(PBS, 0.5% Triton X 100, 10 mM DTT, 1 mg/ml lysozyme, 1:1000 protein inhibitor 
cocktail),incubated on ice for 30 min followed by sonication. The resulting lysate was 
cleared of debris by centrifugation at 18,000 × g for 30 min at 4°C.  Supernatant was 
stored at -20° C until purification.   
  
 Purification of Recombinant Proteins 
 Supernatant containing soluble expressed protein was diluted with 1x PBS and 
loaded onto either glutathione agarose (Molecular Probes) or Dynabeads His-tag 
Isolation and Pulldown magnetic beads (Invitrogen). The lysate was allowed to mix with 
the beads overnight at 4° C with rotation in order to facilitate binding.  The glutathione 
sepharose was spun at 1000xg for 1 minute and washed with 10 volumes of PBS 5x.  
Purified proteins were either used for pull-down interactions with beads or eluted off the 
beads with 5mM reduced glutathione in Tris-HCL buffer, pH 8.  Dynabeads were 
collected using a magnet and washed 5x with phosphate buffer (100 mM Na-
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Phosphate, pH 8, 600 mM NaCl, 0.02% Tween 20).  Purified proteins were either used 
for pull down interactions on beads or eluted off the beads with elution buffer 
(phosphate buffer, 300 mM imidazole).  The eluted proteins were concentrated and the 
buffer was exchanged for PBS in a centrifugal filter device (Millipore) with a 10 kDa 
cutoff.   
  
 Mutagenesis of PfMKP1 Dual-Specificity Phosphatase (DUSP) Domain   
 The DUSP domain construct was used for site-directed mutagenesis (SDM).  
Vector pGex-2T with the DUSP domain was used as a template for SDM.  Two 
mutagenesis reactions were performed, C388A and I398R (see Table 3.1 for primer 
sequence), using overlapping PCR of the plasmid.  Plasmids were ligated and 
transformed into DH5-alpha for propagation and sequence confirmation.  After 
sequences were confirmed, plasmids were prepared from the correct clones and 
transformed into BL21 cells for expression.  Expression and purification of proteins was 
conducted as stated above.   
  
 p-Nitrophenyl Phosphate and Fluorescein Diphosphate Protein 
Phosphatase Assays  
 Purified proteins were incubated with p-Nitrophenyl phosphate (pNPP) (Anaspec) 
or fluorescein diphosphate (FDP) (Anaspec) for 1 hour at 37° C in a 96-well plate. The 
OD405 was measured for pNPP wells and the Excitation/Emission (485/528 nm) was 
measured for wells containing FDP substrate using a Spectramax M2 (Molecular 
Devices) plate reader and Softmax Pro (v. 5.4.5). Samples to which no enzyme was 
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added were used as negative (-) controls.  Alkaline phosphatase was incubated with 
substrate as above for a positive (+) control.  Purified GST protein with substrate was 
used as a normalizer of background.  All results were subtracted by GST readings in the 
figure.  Results are given as the average of 2 wells.  The experiment was repeated 
twice with a representative assay reported.   
  
 Recombinant Protein Pull-Down Assay   
 Recombinant PfMKP1 proteins and Pfmaps were expressed in E. coli as above.  
The pull-down was performed as described in manufacturer’s protocol (Invitrogen).  
Briefly, purified PfMKP1 proteins (DUSP, RHD, RHD+DUSP) were incubated with 
Pfmap1, Pfmap2, or NusA only bound to Dynabeads for 2 hours at 4° C with continuous 
mixing.  Beads were washed 10x with pull-down buffer (6.5 mM Na-Phosphate, pH 7.4, 
140 mM NaCl, 0.02% Tween-20).  Bead and protein mixture were resuspended in 4x 
reducing SDS buffer and subjected to SDS-PAGE followed by western blot with anti-
GST (Sigma).      
  
 Parasite Lysate Pull-Down Assay   
 Recombinant full-length PfMKP1 (RHD + DUSP domain) and GST only were 
expressed in BL21 and purified using glutathione agarose overnight at 4° C as 
described above.  Mixed stage P. falciparum NF54 iRBCs were collected by 
centrifugation and saponin lysed followed by extensive washing in PBS to remove RBC 
proteins.  Free parasites were resuspended in lysis buffer (1% TX100, 50 mM Tris–Cl 
pH 8.0, 5 mM EDTA with complete protease inhibitor cocktail (Sigma) and phosphatase 
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inhibitor) and lysed on ice for 30 minutes.  Samples were subjected to centrifugation 
(14,000xg) for 15 minutes to remove insoluble proteins.  The soluble portion 
(supernatant) was used for the pull-down assay.  Agarose with bound PfMKP1 of GST 
were mixed with P. falciparum NF54 cell lysate and incubated with constant rotation for 
1 hour at 4° C.  The beads were spun at 1000xg for 1 minute and washed 10x with PBS 
+ Tween-20.  The beads were then resuspended in reducing SDS buffer and run on a 4-
12% gradient gel Tris-glycine gel.   
  
 Mass Spectrometry Identification of Parasite Proteins from Pull-Down 
Assay 
 After SDS-PAGE, the gel was stained with Coomassie blue followed by 
destaining. Protein bands were seen throughout the lane.  Each lane was cut into 10 
sections and further processed for analyzing by LC-MS/MS.  The gel pieces were 
processed to remove all SDS, reduction and alkylation of the proteins and then in-gel 
digestion using trypsin (Promega).  The digested proteins were resuspended in 0.1% 
formic acid and run on a 60-minute gradient for MS/MS on a linear ion trap nLC/MS 
(LTQ XL, Thermo) equipped with XCalibur (version 2.0.7) data acquisition software.  
The resulting identified peptides were run against a merged Homo sapiens - P. 
falciparum database from UniProt (http://www.uniprot.org/) using Mascot (Matrix 
Science, London, UK; version 2.2).  The identified proteins were analyzed using 
Scaffold (version Scaffold_3_00_08, Proteome Software Inc., Portland, OR) to validate 
MS/MS based peptide and protein identifications. Peptides were accepted if the 
probability was > 95.0% as specified by the Peptide Prophet algorithm and protein 
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identifications were accepted at probabilities > 95% as specified by the Protein Prophet 
algorithm.  To determine significant enrichment of proteins a Fisher’s exact test was 
used and the p-value is given in the figure.      
  
 Parasite Culture 
 P. falciparum NF54 wild-type, C9 mutant parasite, and complemented mutant 
were used for this study.  The piggyBac mutant parasite line C9 and the complemented 
piggyBac mutant (C9 complement) were previously described (2).  All cultures were 
maintained using standard techniques.  Plasmodium falciparum wild-type NF54 and the 
mutant clones were cultured according to standard methods at 37°C and gassing (5% 
O2 and 5% CO2, nitrogen balanced) with 5% hematocrit (O+ blood, Interstate Blood 
Bank) in RPMI 1640 medium (Invitrogen) supplemented with 0.5% Albumax II 
(Invitrogen), 0.25% sodium bicarbonate and 0.01 mg/ml gentamicin. The complemented 
piggyBac mutant was maintained with 2 μg/ml Blastocidin-D to maintain the episome.  
Parasite lines were kept in culture for no longer than 3 months as to keep the integrity of 
the transposon insertion and minimize antigenic variation.   For assays, parasite lines 
were synchronized during ring stage a minimum of 2x using 5% sorbitol unless 
otherwise stated. 
   
 P. falciparum Protein Extraction and Western Blot 
 Parasite culture was synchronized twice with 5% sorbitol and parasites were 
harvested 5 hours later for ring stage and 28 hours later for trophozoites stage.  All 
parasites were harvested by incubating with PBS with 0.1% saponin in order to lyse 
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RBCs.  Cells were washed 3x to remove RBC debris and the resulting parasite pellet 
was suspended in SDS-PAGE buffer.  For ring stage parasites, parasitemia was 
equalized to 5% between cultures.  For trophozoites stages, culture was harvested and 
iRBCs were purified through MACS magnetic column (Miltenyi Biotec).  The purified 
iRBCs were counted by hemocytometer and adjusted to 1 x 10^7 cells/ml to standardize 
the number of iRBC across strains.    Samples were loaded onto a gradient SDS-PAGE 
gel and western blot was conducted in the same manner as stated above using Mouse 
anti-PyBiP (a gift from Sebastian Mikolajczak, unpublished) at 1:1000 and Rabbit anti-
Pfmap1 (a gift from Christian Doerig) at 1:1000 or Rabbit anti-Phospho-p44/42 MAPK 
(Erk1/2) (Cell Signaling; proprietary synthetic phosphopeptide corresponding to 
residues surrounding Thr202/Tyr204 of human p44 MAP kinase) at 1:2000.  Secondary 
HRP conjugated goat anti-rabbit or anti-mouse (Jackson Laboratories) was used at a 
1:10,000 dilution.  Densitometry on the resulting bands was conducted using a 
PharosFX Plus imager (Biorad) and Quantity One software.  
  
 Pfmap1 Localization within the Parasite 
 Late stage parasites after synchronization were purified using MACS magnetic 
column (Miltenyi Biotec).  The iRBCs were fixed in solution and processed for 
immunofluorescence using methods previously described (30).  Rabbit anti-Pfmap1 
(1:500) was used for the primary and Anti-Rabbit Alexa Fluor® 594 (Life Technologies) 
was used for the secondary.  Hoechst 33342 (10 μg/ml) was used to stain the nuclei.  
Parasites were visualized by a DeltaVision CORE microscope (Applied Precision).   
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Results 
  
 Recombinant PfMKP1 Shows In vitro Phosphatase Activity 
 Bioinformatic analysis of PfMKP1 predicted it is an inactive phosphatase or has 
significantly reduced activity due to mutations in the active motif CX5R (2). To determine 
if PfMKP1 possesses phosphatase activity, we expressed and purified single domain 
and dual domain PfMKP1 as GST fusion proteins from E. coli for a generic substrate 
phosphatase assay (Fig. 3.1B). We used PfYVH1, a known DUSP in P. falciparum (17), 
as a positive control for the assay.  The DUSP domain and the full-length protein 
demonstrated similar activity to a positive control while the RHD domain alone showed 
no enzymatic activity (Fig. 3.2A).  To further demonstrate if the altered CX5R motif was 
involved in decreasing enzymatic activity, the DUSP domain was mutated in suspected 
residues of catalytic activation (Fig. 3.1C).  Unexpectedly, the mutation of C383A in the 
DUSP domain increased activity of the enzyme while the mutation I399R decreased 
activity to background level (Fig. 3.2A).  The assay was repeated in a generic peptide 
substrate assay and again the mutated DUSP C383A demonstrated increased activity 
compared to the wild-type DUSP and full-length domain (Fig. 3.2B).  The data shown 
are representative of data obtained from independent purifications. 
  
 In vitro Binding of PfMKP1 to Pfmaps 
 Single domain and dual-domain recombinant PfMKP1 proteins were used to test 
in vitro interaction with Pfmap1 and Pfmap2.  The dual-specificity (DUSP) domain was 
able to bind both Pfmap1 and Pfmap2 but not the NusA only control (Fig. 3.3A).  Both 
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the single rhodanese (RHD) domain and the dual-domain proteins (RHD+DUSP) bound 
only to Pfmap1 and not to either Pfmap2 or NusA (Fig. 3.3A).  Furthermore, interaction 
of the recombinant full-length PfMKP1 protein was tested against parasite lysate to see 
if native Pfmaps bind to PfMKP1.  Both the full-length PfMKP1 and GST only (control) 
were produced and bound to glutathione agarose.  P. falciparum NF54 lysate was 
incubated with both samples.  The beads were washed and run on a SDS-PAGE gel.  
The entire lane of the gel was cut out and divided into 10 samples for LC-MS/MS 
analysis.  Five proteins were enriched in the PfMKP1 sample as compared to the GST 
only (Fig. 3.3B) including Pfmap1 (p = 0.011).  Pfmap2 was not found in the protein 
identification.  
  
 Pfmap1 in vivo Expression and Phosphorylation 
 Pfmap1 expression was determined in both the early ring stages and the late 
trophozoite stages of the parasite life cycle in NF54 wild type, C9 mutant, and C9 
complemented parasite lines.  Pfmap1 was found to be expressed throughout all stages 
of the life cycle (Fig. 3.4A, top panel) which is similar to previous work (12).  We used a 
commercial antibody that recognizes the pTpY motif of MAPK ERK1/2.  This antibody 
was predicted to recognize phosphorylated Pfmap1 TDY motif based on sequence 
homology.  We found that the active site of Pfmap1 TDY is phosphorylated in late 
trophozoite stage but not in ring stage (Fig. 3.4A, middle panel).  In the C9 mutant, the 
phosphorylated motif was increased as compared to the wild type and the complement.  
Based on densitometry of the bands, the proportion of phosphorylated to total Pfmap1 
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was higher in the mutant (52%) compared to less than 10% for the wild-type and 
complement (Fig. 3.4B).   
  
 Pfmap1 Localization in Late Stage Parasites   
 Localization of Pfmap1 was determined by immunofluorescence assay (Fig. 3.5) 
in the late stages of the cell cycle where PfMKP1 would be highly expressed and the 
phosphorylated form of Pfmap1 is more highly expressed.  Pfmap1 was found diffused 
through the cytoplasm in both the wild-type and complemented C9 mutant.  In contrast, 
in the C9 mutant, Pfmap1 appeared more in a nuclear, punctate pattern rather than 
diffused through the cytoplasm (Fig. 3.5).  This localization pattern was seen in at least 
5 parasites per parasite line used. 
 
Discussion 
 PfMKP1 was previously described as an atypical MAPK phosphatase which 
affected erythrocytic growth of P. falciparum by lengthening the cell cycle in the pre-S 
phase (2).  Here we have further described the characteristics of this protein.  We found 
that PfMKP1 dual-specificity domain does confer phosphatase activity to the protein in a 
generic substrate phosphatase assay.  Interestingly, we found that mutating the Cys in 
the predicted CX5R motif to an Ala increased phosphatase activity in the generic 
substrate assay.  This unusual result was repeated with a separate assay and found to 
be similar.  This could indicate that the canonical CX5R (or the atypical CX14I seen in 
PfMKP1) motif is not responsible for catalytic activity of the enzyme and therefore other 
residues should be explored.  Specifically, there are 2 Lys residues found within the 
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CX14I motif that in a homology model forms a loop structure around the putative active 
site and may be involved in the enzymatic activity of the protein (4).   In addition, the 
aspartic acid which is present in the active site pocket of PfMKP1 could act as acid-
base catalysis to remove a phosphate group taking the place of the catalytically 
important cysteine.   
 PfMKP1 is a type II MKP which possesses 2 domains, an inactive rhodanese 
(RHD) and an active dual-specificity phosphatase domain (DUSP).  We further wanted 
to explore if PfMKP1 uses one of the two MAPKs found in the P. falciparum genome, 
Pfmap1 or Pfmap2, as a substrate.  We found that the DUSP domain binds to either 
Pfmap1 or 2 in an in vitro pull-down assay in vitro but that the full-length protein (RHD + 
DUSP domain) and the single RHD domain would only interact with Pfmap1.  
Furthermore, a pull-down using recombinant full-length PfMKP1 was able to enrich for 
native Pfmap1 from parasite whole cell lysate.    In type II MKPs, the inactive rhodanese 
domain confers substrate specificity and acts as a MAPK binding domain (MKB) (15).  A 
kinase interaction motif (KIM) is typically found within MKB domains and allows for 
binding specificity with its MAPK partner (24).  MAPKs contain a common docking 
domain with a conserved DXXD motif found on the opposite side of the active pocket on 
the MAPK which enable specificity of its interaction with both MAPKKs and MKPs (28).  
We hypothesize that a stretch of amino acids in the RHD domain (aa167-182: 
IYNKKMMIQINKEM) act as a KIM (Appendix B) that potentially interacts with a common 
docking domain in Pfamp1 (aa316-319: SIID) (Appendix B).          
 The expression of PfMKP1 affected the phosphorylation and localization of 
Pfmap1.  We found that the expression of Pfmap1 in the mutant was unchanged (or 
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slightly lower, possibly due to feedback mechanisms but not confirmed) compared to 
wild-type and complemented mutant (Fig. 3.4).  However, the phosphorylation status of 
Pfmap1 in the mutant was increased as compared to the wild-type and complemented 
mutant (Fig. 3.4).  Furthermore, Pfmap1 in the mutant parasite line is localized in the 
nuclear region compared to diffused throughout the cytosol in the wild-type and 
complemented mutant (as seen in previous studies (7)).  Recently, P. berghei map1 
was found to be localized to the nucleolus of the parasite in liver stages enabled by its 
conserved nuclear localization sequence (NLS) found in all map1 orthologues in 
Plasmodium (33).   
 Localization of Pfmap1 using rabbit polyclonal anti-Pfmap1 did give background 
in the immunofluorescence.  In order to fully demonstrate that translocation of Pfmap1 is 
occurring, differential protein preparations could be used to assay for the kinase in 
nuclear versus cytosolic preps as was performed in PfYVH1, another enzyme predicted 
to be part of the MAPK pathway (17).  In addition, more quantitative analyses of IFAs 
using a cytosolic and nuclear protein marker and looking for co-localization of Pfmap1 
with either marker could definitively prove the translocation of Pfmap1 during the 
parasite life cycle and in response to phosphorylation of the TXY motif.  Taken together, 
both the increased phosphorylation and the change in localization patterns, indicates 
that the Pfmap1 may stay activated in the mutant parasite line longer than in the wild-
type.  This over-activation of Pfmap1 may lead to the phenotypic changes we saw in the 
mutant cell line, such as cell-cycle lengthening and increase in knob surface structures 
((2); Chapter 2).    
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 Pfmap1 has demonstrated kinase activity in vitro that is dependent on the 
phosphorylation of the TDY motif (12).  However, when Pfmap1 was knocked out, there 
was no apparent effect on erythrocytic growth of the parasite and the only phenotype 
was an increase in Pfmap2 expression (7).  Other phenotypes within the Pfmap1 
knockout have yet to be studied and the effect of overexpression or overstimulation of 
this kinase in the parasite is still currently unknown.  When Pfmap1 was heterologously 
expressed in COS-7 cells, the expression of the wild-type version induced apoptosis in 
those cells while a mutant in the phosphorylated TXY motif did not affect the cell growth 
(12).  MAPK over-activation in eukaryotic cells can lead to disease in humans and 
aberrant changes in the growth and phenotype of a cell (5).  Further investigation into 
Pfamp1, PfMKP1, and other enzymes in the pathway may elucidate functions for the 
MAPK pathway in the parasite. 
 The MAPK pathway is important in eukaryotic cells for cell function, growth, and 
differentiation.  The MAPK pathway plays a crucial role in the development of human 
cancer and is of great interest as a drug target, for which there is already one drug 
currently being used in the clinical setting (13).  Based on our data presented here and 
previously reported results, we propose a hypothetical MAPK pathway in P. falciparum 
where PfMKP1 acts a MAPK phosphatase in the cytosol of the parasite (Fig. 3.6) 
controlling the activation of Pfmap1.  Filling in the gaps within this model could lead to 
new targets for drug discovery in malaria.         
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Figure 3.1: Domain Architecture of PfMKP1 and Recombinant Proteins Used in 
Study.  (A) PfMKP1 consists of an inactive rhodanese (RHD) domain followed by a 
dual-specificity phosphatase (DUSP) domain similar to a Type II MAPK phosphatase 
(MKP) where the inactive RHD domain acts as a MAPK binding domain (MKB).  (B) 
Recombinant protein constructs made for this study. GST fusion proteins, PfMKP1 
(RHD, DUSP, RHD + DUSP) and PfYVH1, and His6 -tag (black bar) proteins, Pfmap1, 
Pfamp2, and NusA.  (C) Conserved active motif CX5R in human MKP3 and the atypical 
motif found in PfMKP1.  Site-directed mutagenesis of putative critical residues in the 
DUSP domain of PfMKP1 are shown in bold. 
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Table 3.1: Constructs Made in this Study for Production of Recombinant Protein. 
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Figure 3.2: Recombinant PfMKP1 has Phosphatase Activity. (A) Phosphatase 
activity was present in DUSP, DUSP C383A, full-length (RHD+DUSP), and YVH1 in a 
pNPP generic substrate phosphatase activity.  (B) DUSP C383A demonstrated higher 
activity than DUSP, full-length PfMKP1, and YVH1 in a generic peptide-based (FDP) 
phosphatase assay.   
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Figure 3.3: PfMKP1 Interacts with Pfmap1. (A) A pull-down using Pfmap1 and 2 (or 
NusA) as bait protein and recombinant PfMKP1 RHD (R), DUSP (D), or the full-length 
protein (RD) as prey. A western blot using anti-GST illustrates the binding of bait and 
prey proteins. (B) nLC-MS/MS analysis of parasite proteins bound to recombinant 
PfMKP1 full-length construct (RHD+DUSP) or GST control.  The table indicates number 
of spectra associated with the protein identified by nLC-MS/MS and the p-value 
(Fisher’s exact test) indicates significant enrichment in the full-length PfMKP1 sample.  
All proteins were identified at 95% protein identification probability score. PlasmoDB ID 
(v.11.0, www.plasmodb.org/).     
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Figure 3.4: In vivo Expression and Phosphorylation of Pfmap1 in P. falciparum 
NF54 Wild-type, C9 Mutant, and Complemented (Comp) Mutant. (A) 
Phosphorylation status of Pfmap1 TXY motif (anti-pTpY; top panel) and overall 
expression of Pfmap1 (middle panel) throughout the life cycle. Anti-PyBiP was used as 
a loading control.  (B)  Densitometry of the bands shown in (A).  Graph on left shows 
densitometry units as measured and graph on right shows the percent of 
phosphorylated Pfmap1 (units of anti-pTpY/units of Pfmap1 x 100). 
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Figure 3.5: Changes in Pfamp1 Localization in P. falciparum C9 Mutant.  Infected 
RBCs (NF54 wild-type, C9 mutant, and C9 complemented mutant) were harvested ~28 
hours post-infection and subjected to immunofluorescence assay using anti-Pfamp1 
and Hoechst for nuclear visualization.   
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Figure 3.6: Simplified Schematic of Hypothetical MAPK Pathway in P. falciparum. 
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CHAPTER FOUR: 
DEVELOPMENT OF A MULTIPLE REACTION MONITORING ASSAY FOR 
TRACKING THE ACTIVATION OF THE MAPK PATHWAY IN PLASMDOIUM 
FALCIPARUM 
 
Introduction 
 Mitogen-activated protein kinase (MAPK) pathways play important roles in 
eukaryotic cellular response to external stimuli (4, 13).  Once a signal is transmitted 
through the cellular membrane, MAPKs (such as ERK, JNK, or p38 within human cells) 
are activated by the phosphorylation cascade and affect overall transcription of the cell.  
Mitogens (growth factors) were originally found to be activators of this pathway but other 
signaling molecules such as pheromones and stress-inducing substances can also turn 
on this pathway (4). MAPKs contain a conserved TXY motif that is phosphorylated by 
an upstream kinase when the pathway is activated from on outside stimuli (3). In an 
activated state, both residues (Thr, Tyr) must be phosphorylated in order for the kinase 
to bind the appropriate substrate.  This phosphorylation event specifically determines 
the active state of the kinase.   
 Plasmodium falciparum is an intracellular human parasite that is of great public 
health importance as it causes close to 1 million deaths per year worldwide (7).  There 
are two MAPKs in the P. falciparum genome.  Pfmap2 is an atypical MAPK with a 
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signature TSH motif and has been shown to be critical to the parasite life cycle (5, 6).  
Pfmap1 is a typical MAPK which contains a canonical TDY motif that has been shown 
to be necessary for catalytic activity in vitro (8).  Pfmap1 can be knocked-out and 
parasite growth can continue in the erythrocyte in in vitro culture (5).  However, the 
effects of overexpression or over-activation of this kinase have not yet been studied.   
 Pfamp1 is most closely related to the human homologue ERK2 which is involved 
in cell growth, differentiation, adhesion, and cytoskeletal rearrangement (2).  However, 
because P. falciparum has only 2 MAPKs compared to a much expanded MAPK family 
in humans, Pfamp1 may take on extra roles within the cell and may also act in stress 
response.  Stressors may have different phenotypic effects on the parasite such as 
dormancy or gametocytogenesis for which the mechanism of each is still unknown in 
Plasmodium. Therefore, it is possible that Pfmap1 activation could act as a reporter for 
cellular stress triggered by events such as drug pressure, osmotic pressure, waste 
exchange or other environmental conditions.   
 Multiple reaction monitoring (MRM) utilizes retention time and mass-to-charge 
ratio selectivity of peptides to robustly quantify proteins without labeling (1).  MRM has 
been used to successfully determine the stoichiometry of phosphorylated proteins in 
organisms including yeast, mice, and human cells (1, 10, 11).  An MRM workflow can 
allow for the relative quantification of phosphorylated versus non-phosphorylated protein 
in treated versus untreated cultures.  In this work, we describe a novel MRM method to 
monitor the phosphorylation status of Pfmap1 in P. falciparum.   
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Methods  
  
 AQUA Peptides for Assay   
 Pfmap1 has been previously characterized and the activation motif TDY has 
been identified as dually phosphorylated in previous phosphoproteome analyses of 
Plasmodium falciparum (12).  In order to monitor the phosphorylation status of this 
motif, the tryptic peptide was determined based on in silico digestion of the protein 
sequence (taken from PlasmoDB v.11.0; www.plasmodb.org/).  All phospho-variations 
of this peptide were chosen for quantification (Table 4.1).  In addition, two peptides for 
overall quantification of the protein were chosen using Skyline© (64 bit, v. 1.3.0.3735, 
University of Washington) with the following criteria: no Cys, His, Met, NXS/T, RP/KP, or 
missed cleavages.  Resulting peptides were tested for uniqueness against a merged 
database of Plasmodium-human protein sequences obtained from UniProt.  Based on 
this criterion, two peptides were chosen for synthesis (Table).  All peptides were 
synthesized by ThermoFisher Scientific as HeavyPeptideTM AQUA Basic peptides with a 
heavy Arg residue (13C6; 15N4) with the exception of GAYGVVFK which had a heavy 
Lys residue (13C6; 15N2). All peptides were rehydrated in water and stored at -20 C in 
aliquots.   
  
 Multiple Reaction Monitoring (MRM) Methods Development 
 The top three MRM transitions from each AQUA peptide’s precursor mass-to-
charge ratio (m/z) were determined via syringe-pump infusion in the tune mode of a 
triple quadrupole mass spectrometer (TSQ Quantum Ultra, Thermo). Ion transmission 
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optics for both precursor and product ions and product collision energies were optimized 
in this mode as well. Product ions were determined empirically for the heavy-labeled 
AQUA peptides and deduced for the unlabeled native peptides based on the loss of 8 
(Lys) or 10 (Arg) for all Y ions (Table).   
 To determine the limit of detection (LOD) and limit of quantification (LOQ) for 
each peptide standard, five microliter injections of mixed serially diluted AQUA peptides 
(25-5000 fmol) were separated by reverse-phase HPLC on an Eksigent NanoLC 2D 
Ultra system (Dublin, CA, USA) using an analytical column (ProteoPep II™ 75 μm 
i.d. × 10 cm C18) manufactured by New Objective (Woburn, MA, USA) before subjected 
to MS/MS. The mobile phase flow-rate was 350 nL/min and followed a linear gradient of 
0-30 min 0-55% B (mobile phase A = 0.1% FA in water and B = 0.1% FA in acetonitrile). 
  
 Recombinant Pfmap1 Production and LC-MS/MS Analysis   
 Pfmap1 containing plasmid was a gift from Isabelle Lucet.  The cloning and 
production of protein is outlined in Chapter 3 methods.  Purified recombinant Pfmap1 
was diluted 1:2 in a series and subjected to SDS-PAGE on a 10% Tris-Glycine gel.  The 
gel was stained with coomassie and destained.  The subsequent Pfmap1 band (Fig. 
4.3A) was cut from the gel and washed with acetonitrile to remove SDS.  The gel slice 
was then subjected to reduction, alkylation, and trypsin (Promega) digestion.  The 
digested protein was extracted from the gel with acetonitrile and formic acid, speed 
vacuumed to dryness and resuspended in 0.1% formic acid for mass spec analysis.  
The resulting peptides were automatically injected using an autosampler into a reverse 
phase nano-HPLC followed by triple quadrupole MS/MS as described above.     
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RESULTS 
  
 Development of Assay Using AQUA Peptides   
 Mass transitions of AQUA peptides were determined by single peptide direct 
infusions into the triple quad MS.  Transitions were chosen based on uniqueness to the 
given peptide.  The precursors and transitions monitored for each AQUA peptide are 
listed in the Table 4.1.  Because the target peptide only differed in phosphorylation of 
residues, transitions overlapped and only one product ion m/z was unique for individual 
peptides.  However, given different retention times (Fig. 4.1) of the peptides and 
different parent ion m/z (for most), peptides could be individually monitored.  The LOQ 
was determined for four of seven AQUA peptides (Fig. 4.2). Unphosphorylated peptide, 
control peptides, and the singly phosphorylated tyrosine peptide were detectable 
starting at 200 fmol.  However, the other phosphorylated peptides were not detectable 
even in the 1-5 pmol range and therefore the LOD and LOQ could not be determined.   
  
 MRM Assay Using Recombinant Pfmap1   
 Recombinant Pfmap1 was expressed as described previously (Chapter 3 
methods).  The recombinant protein was diluted 1:2 in a series and subjected to SDS-
PAGE.  The purified protein bands (Fig. 4.3A) were excised and run through nLC-
MS/MS on a triple quadrupole MS using the transitions developed with the AQUA 
peptides.  Pfmap1 recombinant protein was robustly detected using the 
unphosphorylated target peptide and the control peptides for total protein quantification 
(Fig. 4.3B) even when small amounts were noticeable on the gel.     
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Discussion 
 Here within, we describe a novel method for the robust quantification of 
phosphorylated Pfmap1 in Plasmodium falciparum blood-stage cultures.  Pfmap1 
phosphorylation activates the kinase which may play an important role in the cellular 
response to stimuli whether mitogenic or stress-inducing.  This method can be used to 
track cellular effects due to drug treatment or other stress or growth signals on the cell.  
However, this method needs more refinement in order to fully function as a screening 
tool: 1) to identify the true limits of detection and limits of quantification of 
phosphorylated peptides and 2) purification of native Pfmap1 that is unbiased to 
phosphorylation status.    
 Attempts using unenriched parasite lysate to identify Pfmap1 in LC-MS/MS were 
unsuccessful.  P. falciparum NF54 proteins were extracted from 50-100 ml of a 10% 
parasitemia culture in order to identify Pfmap1 phosphorylated and unphosphorylated 
forms.  The protein lysate was run on a SDS-PAGE gel where the lanes were cut into 
10 fractions and in-gel digestion was performed.  The resulting peptides were run 
through a linear ion trap (LTQ XL, Thermo) mass spectrometer with 90 minute 
gradients.  Despite multiple attempts at identifying Pfmap1 in unpurified protein lysate, it 
was never detected in the resulting spectra.  Previously, Pfmap1 was found to be 
processed during the P. falciparum erythrocytic life cycle (8) and may represent a 
challenge in quantifying the active kinase form.  An enrichment of Pfmap1 may reduce 
the milieu of proteins and allow for identification of Pfmap1 as previously done through a 
pull-down with interacting partners (Chapter 3) or through phosphoprotein enrichment 
(12).  However, the enrichment step should not be biased to the phosphorylation state.  
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An endogenous tag of the gene would be able to provide an unbiased method for 
purification.  Another issue that was not originally considered was that in previous work 
(unpublished) the peptide containing the TDY motif was found as a missed cleavage 
(Lys precedes the Val).  In order to minimize the presence of a missed cleavage, a 
double digestion with trypsin and Lys-C enzyme may be utilized.   
 There have been previous publications using this method to determine the 
phosphorylation status of MAPKs in yeast (9) and the method could be very robust at 
detecting cellular changes due to stress however more work is needed to optimize 
many of the conditions (i.e. protein ID, peptide ionization, and potential missed 
cleavages).  This method can be applied to determine what extracellular stimuli activate 
the MAPK pathway by monitoring the phosphorylation status of the MAPK Pfmap1 TXY 
motif (Fig. 4.4).  Pfmap1 activation may have significant effects on the cell as seen in 
the C9 mutant (See previous chapters).  This screen could determine compounds that 
cause stress and could lead to the identification of the mechanisms behind drug 
resistance and gametocytogenesis in Plasmodium, two important phenomenon that are 
critical for the control and treatment of this deadly disease.  In addition, as the piggyBac 
mutant library expands towards saturation, we can test mutant strains of putative 
kinases and phosphatases to determine if they are upstream enzymes in the MAPK 
pathway allowing for elucidation of the pathway.  More work that looks at signaling 
events could lead to a better understanding of the parasite biology and further 
development of treatment methods.     
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Table 4.1: AQUA Heavy Labeled Peptides Used in Multiple Reaction Monitoring 
Experiment.   
 
 
Lower case (t or y) indicates phosphorylated residue.   
* indicates neutral loss ion (y-H3PO4) 
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Figure 4.1: Retention Time of Representative AQUA Peptides in Reverse-Phase 
Nano-LC/MS.   
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Figure 4.2: Limit of Detection for AQUA Peptides.  AQUA peptides were serially 
diluted and run on a triple quadrupole mass spectrometer.  Resulting areas under the 
curves are shown here and the respective R-squared value indicating good linear 
quantification in the fmol range. 
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Figure 4.3: Pfmap1 Recombinant Protein Expression and Peptide Analysis Using 
MRM.  (A) Coomassie stained Tris-Glycine gel showing purified recombinant protein 
Pfmap1 in a dilution series.  (B) The protein bands in (A) were subjected to in-gel 
digestion and nLC-MS/MS.  Three peptides were used to monitor the amount of protein 
in each sample.  Numbers correlate bands on gel with nLC-MS/MS results.   
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Figure 4.4: Workflow for Multiple Reaction Monitoring (MRM) Experiment.   
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CHAPTER FIVE: 
CONCLUSIONS 
 
Discussion 
  
 Development of Screen for Cytoadherence Phenotype in piggyBac Mutants  
 Cytoadherence is an important pathogenic mechanism that allows P. falciparum 
to cause high mortality rates (1, 9).  Within this work, we have given proof of principle 
for a quantitative cytoadherence screen that can be scaled to test multiple P. falciparum 
strains at a time.  During the course of our screen, we found that insertions in genes 
with ontologies in protein modification, nucleic acid metabolism, and other unknown 
genes affect cytoadherence of the parasite.  We found these groups enriched in both 
those parasites that are increased in cytoadherence and those that are decreased 
compared to the wild-type.  We further found that individual exported proteins did not 
affect overall cytoadherence of the cell.  A caveat to this is some mutants that have 
undergone antigenic switching to another var gene in culture demonstrated decreased 
binding to CD36.  In these mutants, it cannot be verified as a defect in binding due to 
the transposon insertion in a gene or due to the antigen switching.  It is interesting to 
note that some mutants in which the var gene expression switched had transposons 
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inserted upstream of the original var gene which may have contributed to the cause of 
the switch in expression.   
 A similar screen was designed for use in screening compounds to look for 
inhibition of iRBCs bound to receptor CSA, which is involved in placental malaria (12).  
An advantage to our screen is that we do not have a proprietary formula and are giving 
free access to other researchers to use our methods.  Both approaches use similar 
image-based methods, however they differ in the analysis and calculations.  Although it 
was not directly tested, there is no reason to believe that these approaches cannot be 
substituted for each other as both approaches were shown to reliably quantify a wild-
type parasite dilution series (Chapter 2, (12)).   
  
 Further Characterization of PfMKP1 
 Previously we described an atypical mitogen-activated protein kinase 
phosphatase (MKP) in the Plasmodium falciparum genome as involved in control of cell 
cycle timing (2).  Within this work, PfMKP1 was characterized further both 
phenotypically and biochemically.  We found that the piggyBac insertional mutant C9 
eliminated expression of PfMKP1 and demonstrated increased cytoadherence due to an 
increase of knobs on the surface of the iRBC (Chapter 2).  Although we could not 
determine how PfMKP1 directly affected the number of knobs on the surface, we 
hypothesize that PfMKP1 is an important phosphatase that controls phosphorylation 
within the protein export pathway.  Further work will need to be done to determine the 
global change in phosphorylation of the C9 mutant versus the wild-type to further 
explore this hypothesis. 
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 We also found that although PfMKP1 has an altered CX5R motif it retains 
catalytic ability and evidence suggests it uses Pfmap1 as at least one of its substrates.  
This places PfMKP1 as a newly identified enzyme in the hypothetical MAPK pathway of 
P. falciparum.  This pathway is not fully known to exist in P. falciparum or in other 
parasitic protozoan, however all eukaryotes from yeast to humans possess this pathway 
in some form and it is likely that it also exists in Plasmodium species.  The complication 
in determining enzymes in the pathway is due to P. falciparum’s AT-rich genome and its 
divergent protein sequences that do not allow for easy identification of homologues.  
Experimental and bioinformatics analysis of hypothetical proteins in this pathway (Fig. 
5.1) has led to the identification of kinases and phosphatases that can act in this 
pathway however more empirical evidence is needed to support the existence of this 
pathway.   
 
Looking Forward 
 
 Mitogen Activated Protein Kinase Pathway 
 The existence of the MAPK pathway in P. falciparum could have a significant 
impact on the biology of the parasite and the way we treat and control parasite 
infections.   Recently, a MAPK inhibitor was found to inhibit P. falciparum cell growth 
(5).  In order to fully define the pathway, proteins must be identified including receptor 
proteins that transmit the signal to the inside of the cell and the activators and 
deactivators of the pathway.  Importantly, MAPKs traditionally translocate into the 
nucleus where they interact with transcription factors to affect transcription.  
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Determining the transcription factors that interact with MAPKs could lead to 
identification of target genes of this pathway.  The ApiAP2 transcription factors have 
recently received attention for their involvement in important cellular regulation (13).  In 
mammalian cells, MAPKs can control both the expression of AP-2 transcription factors 
and the binding of AP-2’s to DNA (11, 19).  Although ApiAP2’s are divergent from 
mammalian and closer to plant AP2 transcription factors (13), they are still involved in 
transcriptional regulation and their activators and repressors are currently unknown. 
 MAPK pathways can be turned on by both abiotic and biotic factors that can 
contribute to stress response, cell differentiation, and cell growth (7, 14, 20).  Cell 
differentiation and cell cycle is under tight control in Plasmodium where it must undergo 
the proper differentiation within the proper environment (3, 4).  Turning on genes for 
sexual development in the hepatocyte of the host could lead to inhibition of parasite 
growth.  Turning on genes in the red blood cell that are involved in exflagellation of the 
parasite could again lead to inhibition of cell growth.  Therefore, the parasite must be 
able to sense its host environment and respond properly by turning on the correct set of 
developmental genes.  Since 1979, it has been known that gametocytes in a laboratory 
setting respond to the use of “spent” media meaning media that contains waste 
products of parasites grown asexually in vitro (6 LH, 1979).  This practice illustrates that 
there is an accumulation of waste product(s) that signal the cell to differentiate sexually 
instead of continuing on the default asexual pathway further indicating that the parasite 
responds to stimuli in the external environment.   
 In addition, a phenomenon that is growing in acceptance is the observation that 
when parasites in the erythrocytic cycle are exposed to drugs, such as artemisinin, they 
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form an environmentally resistant, reduced metabolic state that does not continue to 
progress through the cell cycle until the drug pressure is relieved (8, 10, 15, 16, 18).  
This “dormant” form could be the result of a stress response pathway in the parasite in 
which transcription is inhibited through a negative feedback loop.  Notably, in human 
cancer cells treated with artemisinin, the cell stops its progression in the cell cycle in the 
G1 or G2/M phase (17, 21).   
 Other eukaryotic cellular responses to stress are mediated by the MAPK pathway 
such as osmotic pressure, hydrogen peroxide exposure, and temperature aberrations 
(14).  To further determine the cellular mechanism for stress pathways in P. falciparum, 
monitoring the activation of the MAPK pathway could lead to informative insights on the 
parasite’s ability to sense its external environment and respond.  Based on the results 
published in this work, screens for monitoring Pfmap1 activation are proposed.   
  
 Screens for MAPK Pathway   
 In order to monitor Pfmap1 and its activation state, two biological aspects can be 
considered: 1) activation of the TXY motif through phosphorylation and 2) translocation 
of the protein into the nucleus.   
 Screen one: monitoring Pfmap1 phosphorylation.  MAPKs are activated by 
phosphorylation of the TXY motif.  When activated, the MAPK will translocate into the 
nucleus to affect cell transcription. Chapter 4 described the development of a multiple 
reaction monitoring (MRM) method for robust relative quantification of the TXY 
phosphorylation state of this motif on Pfmap1.  Unfortunately, this method has not come 
to full fruition and still needs experimental development to become a working assay.  
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However, this assay could monitor Pfmap1 status in related mutants to determine if 
other enzymes are acting in this pathway.  For example, sorbitol allows for 
synchronization of intra-erythrocytic cultures but its mechanism is not fully understood. It 
is possible that it causes osmotic stress signaling to the cell in only specific 
developmental stages which may be regulated by Pfmap1.  In addition, cultures could 
be treated with varying substances and screened for activation of this pathway including 
drug treatment, ex. artemisinin. 
  Screen two: Pfmap1 translocation within the cell.  A robust method for the 
localization of Pfmap1 can be useful in determining the active state of the MAPK 
pathway within P. falciparum.    An immunofluorescence assay for Pfmap1 was 
described in Chapter 3 using rabbit anti-Pfmap1.  To scale up this assay, the Operetta 
HCS can be used to determine localization within many parasites under varying 
conditions.  A cytoplasmic marker should be used in addition to the nuclear stain in 
order to provide appropriate contrast for proper analysis by Harmony software.   
Determination of the translocation of Pfmap1 to the nucleus will aid in the ability to 
detect the activation state of the pathway in the cell and the kinase’s effect on 
transcription that lead to changes in parasite phenotype.  These two screens together 
can provide further proof of the MAPK pathway and its role in cellular development.   
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Figure 5.1: A Hypothetical MAPK Pathway in Plasmodium falciparum.   
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APPENDIX A: 
FURTHER CHARACTERIZATION OF PFEMP1 IN C9 MUTANT 
 
Methods 
  
 RNA Isolation, cDNA Synthesis, and Quantitative Reverse Transcription 
(qRT)-PCR 
 RNA was isolated and purified using a TRIzol reagent and following 
manufacturer’s directions (Invitrogen). First-strand cDNA was synthesized by random 
primer mixes using Superscript III Reverse Transcriptase (Life Technologies) according 
to the product manual. PCR primers used for detecting mRNA expression of var genes 
were as described previously (1).  qPCR was performed on a Stratagene Mx300P.  The 
relative standard curve method (ABI User Bulletin #2) was used where genomic DNA 
was used in a standard curve to determine relative copy number and a housekeeping 
gene seryl-tRNA synthetase (PF3D7_0717700) was used to normalize the 
transcriptional level of each var gene.  Parasite RNA was first subjected to degenerate 
primers that identified a group or family of var genes for which individual var genes 
could be tested for.   See Table A.1 for primer sequences.   
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 Immunoflourescence Assay (IFA) 
 Parasites were synchronized as stated previously (Chapter 2) and 
immunofluorescence assays were done as previously described (2). Blood films were 
double-stained with Rabbit anti-Pf332 mAb51-22 diluted 1:500 followed by TRITC-
conjugated Goat anti-rabbit secondary (1:1000) and Guinea pig anti-ATS sera diluted 
1:500 followed by FITC conjugated goat anti-guinea pig secondary (1:1000) (anti-Pf332 
and anti-ATS sera were kind gifts of Denise Mattei).  Nuclei were stained with 0.2 mg/ml 
4′, 6-diamidino-2-phenylindole (DAPI; Molecular Probes). Parasites were visualized by a 
DeltaVision CORE microscope (Applied Precision).   
 
Results 
  
 var Gene Expression Remains Stable  
 We found that P. falciparum NF54, P. falciparum NF54 helper (contains 
transposase episome), and C9 mutant line expressed a var gene that reacted with 
primers in the BC1 and BC2 group (Fig. A.1A).  Since these are degenerate primers, 
overlap is expected.  Based on the grouping BC1/BC2, individual var gene expression 
was tested for with primer pairs that recognized specific var genes (see table).  Of the 
25 different var genes that were tested for, only the 9ʹ primer pair gave distinct results 
for both NF54 wild-type and C9 mutant (Fig. A.1B).  However, none of the 25 primer 
sets tested identified the correct var gene expressed in the helper line.  Moving forward 
with the cytoadherence screen, the helper line was no longer used due to the change in 
var gene expression.  Based on these results, all piggyBac mutant lines used in the 
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cytoadherence screen (Chapter 2) were tested for var gene expression using the 9ʹ 
primer set which correlates to gene ID: PF3D7_0421100. 
  
 Further Study of PfEMP1 in C9 Mutant 
 Due to the change in cytoadherence phenotype (see Chapter 2) in the C9 mutant 
line, we investigated the surface expression of PfEMP1 through western blot (Chapter 
2) and IFA (Fig. A.2).  In the IFA, PfEMP1 was found to associate with Pf332 (a 
Maurer’s cleft marker) and in punctate spots on the surface of the iRBC as expected.  
There was no apparent increase in PfEMP1 surface expression.   
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Table A.1: var Gene Primers Used in Study. 
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Figure A.1: Determination of var Gene Expression in P. falciparum Strains. (A) The 
var gene group was first tested using degenerate primers and then the var gene within 
the group was determined for each strain (B).    
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Figure A.2: Immunofluorescence of P. falciparum C9 Mutant Proteins Involved in Cytoadherence.  Pf332 = 
Maurer’s cleft marker protein, PfEMP1 = Erythrocyte membrane protein 1, DAPI = nuclei stain. 
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APPENDIX B: 
CHARACTERIZATION OF BINDING SITES IN PFMAP1 AND PFMKP1 AND 
PROPOSED SITE-DIRECTED MUTAGENESIS 
 
Methods 
  
 Homology Modeling of Pfmap1 
 Pfmap1 protein sequence was retrieved from PlasmoDB v11.0 (gene ID: 
PF3D7_1431500).  The entire sequence was submitted to Swiss-Model Template 
Identification (http://swissmodel.expasy.org/).  Results of the template identification 
were used in Swiss-Model Workspace to create a homology model ([1, 2] Biasini, M. et 
al., Manuscript in preparation).  The model was viewed and edited using Pymol.v.1.10 
(Schrodinger, 2010).   
  
 Rhodanese Domain Alignment 
 The sequence of PfMKP1 (PF3D7_1305500) and orthologous Plasmodium 
sequences were retrieved from PlasmoDB v11.0 (www.plasmodb.org). Outlier species 
were identified through BLAST searches with the rhodanese (RHD) domain using NCBI 
BLASTP. Sequences with the greatest homology to the PF3D7_1305500 ORF were 
retrieved and used to build the multiple alignment using ClustalW (3, 5).  
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 Site-Directed Mutagenesis of PfMKP1 RHD Domain 
 Plasmid containing E. coli codon optimized PfMKP1 RHD sequence (see 
Chapter 3 methods) was used as the template.  Primers were designed to mutagenize 
the RHD domain (Table B.1) based on previous methods (6).  PCR was used to 
mutagenize the template, followed by ligation of the plasmid and transformation into E. 
coli DH5α (NEB).  Antibiotic resistant clones were propagated in broth and subjected to 
plasmid purification.  Plasmids were sent for sequencing to confirm mutations and 
correct plasmids were subcloned into BL21 expression vector (NEB) and expressed 
following methods outlined in Chapter 3.    
 
Results 
  
 Conserved Sequences in Pfmap1  
 Template identification through Swiss-Model yielded Cryptosporidium parvum 
MapK (PDB ID: 3oz6B) as the top hit.  However, in order to compare to a well described 
MAPK, for subsequent homology modeling the template for human ERK1/MAPK5 (PDB 
ID: 2zoqB) was used. This template had an E value of 1e-67 compare to the E value of 
C. parvum at e-109.  Top hits also included the human MAPK p38 indicating homology 
to more than one type of MAPK.    
 Previous reports have indicated the presence of the catalytically imperative TXY 
motif in Pfmap1 (2, 4).  Here we identify a putative common docking (CD) motif in the 
homology model of Pfmap1 using ERK1 as a template (Fig. B.1).  The CD motif usually 
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consists of a DXXD motif (7).  Pfmap1 has a SXXD (aa316-319) motif in the same 
position as the CD motif (Fig. B.1). 
  
 Identification of a Putative Kinase Interaction Motif in PfMKP1 
 Comparison of the PfMKP1 RHD domain with other RHD domains identified a 
conserved motif indicative of a kinase interaction motif (Fig. B.2).  Typically, this motif is 
arginine rich in other organisms where the arginine residues are critical for binding (1).  
In P. falciparum, the AT-rich genome biases lysine residues therefore in the P. 
falciparum sequence; lysine (K122, K123) takes the place of critical arginine. The KIM 
motif is generally followed by a small stretch of hydrophobic amino acids which are 
present in PfMKP1 RHD domain.  Based on the alignment, we propose the KIM motif in 
the RHD domain is residues 118-132.   
  
Discussion 
 We have identified putative binding domains for both Pfmap1 and PfMKP1 that 
demonstrate how they may interact.  Further work is necessary to confirm the role of 
these motifs in the binding interaction.  Quantitative binding using the Octet ® (ForteBio) 
platform will be used to assess the putative KIM residues using the site-directed 
mutants.  It is hypothesized that all mutants except K59A, K60A, which is a control 
mutation, will show reduced binding to Pfmap1 in vitro.       
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Table B.1: Primers Used for Site-Directed Mutagenesis of PfMKP1 Rhodanese 
Domain.   
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Figure B.1: Homology Model of Pfmap1 Based on ERK1 (2zoqB).  Single asterisk 
indicates putative Common Docking site (SIID) and double asterisk indicates TDY 
active site.   
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Figure B.2: Identification and Mutagenesis of the Kinase Interaction Motif in 
PfMKP1.  (A) PfMKP1 has domains (RHD and DUSP) indicative of a Type II MKP (MKB 
and DUSP) where there is a putative Kinase Interaction Motif (KIM) in the RHD domain.  
(B) Rhoadnese domain of PfMKP1 aligned with orthologues in Plasmodia and other 
organisms.  (Pf= Plasmodium falciparum, Pv = Plasmodium vivax, Pk = Plasmodium 
knowlesi, Pb = Plasmodium berghei, Py = Plasmodium yoelli, Sc = Saccharomyces 
cerevasiae, Sp = Schizosaccharomyces pombe, Dm = Drosophila melanogaster, Hs = 
Homo sapiens). (C) Scheme for site-directed mutagenesis of KIM in PfMKP1 RHD 
domain. KIM is underlined and boxed amino acids were mutated in SDM.   
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